

CURRICULUM VITAE

WILLIAM C. STEWART, MD

**Medical Director
PRN Pharmaceutical Research Network, LLC**

**Director
PRN PharmaFarm, LLC**

TABLE OF CONTENTS

CURRICULUM VITAE	1
EDUCATION.....	3
EXPERIENCE	3
MEMBERSHIPS.....	3
BOARD CERTIFICATION	3
PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES	4
PHARMACEUTICAL STARTUP DEVELOPMENT CONSULTANT	6
VENTURE CAPITAL CONSULTING AND ADVISORY ACTIVITIES	6
CORPORATE MEDICAL ADVISORY BOARD	6
COMPANY BOARD OF DIRECTORS	7
PUBLICATIONS	8
INVITED LECTURES	35
MISCELLANEOUS	54
FELLOWS.....	54
ACADEMIA.....	55
MEETINGS DEVELOPED	56

WILLIAM C. STEWART, MD

CONTACT INFORMATION

E-mail: william.stewart@prnorb.com

Website: <http://www.prnorb.com/>

Blog: <http://prnorb.blogspot.com/>

Mobile: +1.843.327.0316

US Headquarters

Address: 109 East 17th Street, Suite 3407, Cheyenne, WY 82001

Telephone: +1.307.633.9839

Facsimile: +1.307.633.9840

Administrative Office

Address: 104 Berkeley Square Lane, # 286, Goose Creek, SC 29445

Telephone: +1.843.606.0776

Facsimile: +1.888.808.9564

WILLIAM C. STEWART, MD

EDUCATION

07/83 to 06/86: Ophthalmology resident, University of Missouri at Kansas City

7/86 to 6/87: Clinical glaucoma fellowship, Duke University Medical Center, Durham, NC. Training under M. Bruce Shields, MD.

07/82 to 06/83: Private practice, medical director of Minor Emergency Clinic in Garland, TX

07/81 to 06/82: Internal medicine intern at St. Paul Hospital in Dallas, TX

1977 to 1981: Southwestern Medical School, Dallas, TX, Degree earned: MD

1973 to 1977: Southern Methodist University, Dallas, TX, Degree earned: BA (Chemistry)

EXPERIENCE

7/96 to 7/04: Clinical professor of ophthalmology, University of South Carolina, School of Medicine

5/96 to now: Co-Founder and Director of medical affairs, Pharmaceutical Research Network, LLC

7/93 to 5/96: Associate professor of ophthalmology, Storm Eye Institute, Medical University of South Carolina. Chief of the glaucoma service. Granted tenure January 1996.

7/87 to 7/93: Assistant professor of ophthalmology, Storm Eye Institute, Medical University of South Carolina. Chief of the glaucoma service.

MEMBERSHIPS

American Glaucoma Society

Association for Research in Vision and Ophthalmology - Emeritus

BOARD CERTIFICATION

Diplomat of the American Board of Ophthalmology

PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES

- (1) Advisory Board member, **Pharmos Pharmaceuticals**, 1989
- (2) Advisory board member, **Otsuka America Pharmaceutical**, 1994 –1997
- (3) Consultant, R+D, **Ciba Vision Ophthalmics**, 1994 – 1998
- (4) Consultant, Marketing, **Ciba Vision Ophthalmics**, 1996 – 2002
- (5) Advisory board member, **Sandoz Pharmaceuticals**, 1994 - 1995
- (6) Worldwide advisory board member, **Pharmacia Ophthalmics**, 1995
- (7) Worldwide advisory board member, **Ciba Vision Ophthalmics**, 1995
- (8) Chairman, US advisory board, Marketing, **Ciba Vision Ophthalmics**, 1996 –2000
- (9) US Director of glaucoma research, Marketing, **Ciba Vision Ophthalmics**, 2000
- (10) Consultant for product development and FDA liaison, **Starr Pharmaceutical**, 1996
- (11) Brimonidine marketing board member, **Allergan**, 1996
- (12) US advisory board member for latanoprost, **Pharmacia & Upjohn**, 1997
- (13) Consultant, Product Development, **Sommerset Pharmaceuticals**, 1998
- (14) Consultant, Product Development, **Allergan**, 1998
- (15) US Glaucoma Advisory board member, **Merck**, 1998 - 1999
- (16) Co-chairman, HMO Advisory Board, **Pharmacia**, 2002
- (17) Consultant, Outcomes, **Pfizer**, 2003
- (18) Consultant, **InSite Vision**, 2002 – 2003
- (19) Board of Advisors, **Gerson Lehrman Associates**, 2004 – 2005
- (20) Consultant, **Santen Oy**, 2004
- (21) Consultant, **Merck**, 2004
- (22) Consultant, **Acucela, Inc.** 2005
- (23) Consultant, **Inspire Pharmaceuticals, Inc.** 2005
- (24) Consultant, **Peristat Group, Inc.** 2005
- (25) Advisory board member, **Vistakon Pharmaceuticals, LLC** 2006
- (26) Consultant, **Glaukos** 2006

PHARMACEUTICAL CONSULTING AND ADVISORY ACTIVITIES (cont.)

- (27) Consultant, **Vistakon Pharmaceuticals, LLC** 2006
- (28) Consultant, **(OSI) Eyetech, Inc.** 2006
- (29) Consultant, **NovaVision, Inc.** 2007
- (30) Consultant, **XOMA (US), LLC** 2007
- (31) Consultant, **IScience Interventional**, 2007
- (32) Advisory Board member, **NovaVision, Inc.** 2007
- (33) Advisory Board member, **Inspire Pharmaceuticals, Inc.** 2007 - 2009
- (34) Consultant, **Othera Pharmaceuticals, Inc.** 2008 - 2009
- (35) Consultant, **Alcon Laboratories, Inc.** 2007 – 2008
- (36) Consultant, **Vistakon Pharmaceuticals, LLC** 2007 - 2009
- (37) Consultant, **Primus Pharmaceuticals, Inc.** 2008 – 2009
- (38) Consultant, **Icon Bioscience, Inc.** 2009 – 2010
- (39) Consultant, **Sucampo Pharmaceuticals, Inc.** 2009
- (40) Advisory Board member, **Sucampo Pharmaceuticals, Inc.** 2009
- (41) Consultant, **F. Hoffman-La Roche Ltd.** 2010-2012
- (42) Consultant, **Fovea Pharmaceuticals SA** 2010
- (43) Consultant, **Acucela Pharmaceuticals** 2010-2012
- (44) Consultant, **Santen Inc.** 2010
- (45) Consultant, **Altheos, Inc.** 2010-2012
- (46) Consultant, **Inotek Pharmaceuticals Corporation** 2010-2011
- (47) Consultant, **Valeant Pharmaceuticals International, Inc.** 2011-2012
- (48) Consultant, **Sunovion Pharmaceuticals, Inc.** 2012
- (49) Consultant, **Bausch & Lomb, Inc.** 2012
- (50) Consultant, **LayerBio** 2013

PHARMACEUTICAL STARTUP DEVELOPMENT CONSULTANT

- (1) Consultant, **Encore Vision, Inc.** 2011-2014
- (2) Consultant, **BioAvivus, LLC.** 2012
- (3) Consultant, **Aciont, Inc.** 2013-
- (4) Consultant, **Slayback Pharma, LLC** 2013
- (5) Consultant, **Exomemis, Inc.** 2013
- (6) Consultant, **InnoPharma, Inc** 2013
- (7) Consultant, **Trefoil, Inc** 2013-2016
- (8) Consultant, **Undisclosed** 2014-2017
- (9) Consultant, **ViSci (Visual Sciences), Ltd.** 2014
- (10) Consultant, **Aqua Therapeutics Co., Ltd.** 2014
- (11) Consultant, **iSTAR Medical SA** 2014, 2016
- (12) Consultant, **Renaissance Pharma, Inc.** 2014
- (13) Consultant, **Peregrine Pharmaceuticals Inc.** 2016
- (14) Consultant, **Allysta Pharmaceuticals, Inc.** 2016-

VENTURE CAPITAL CONSULTING AND ADVISORY ACTIVITIES

- (1) Consultant, **Nordic Biotech** 2010

CORPORATE MEDICAL ADVISORY BOARD

- (1) Advisory Board member, **PRN Consulting Ventures Corporation** 2010

WILLIAM C. STEWART, MD

MEDICAL MONITOR

- (1) **Peregrine** CS202-203
- (2) **ViSci** VS101-CS201
- (3) **Aciont** DSPV-201
- (4) **InnoPharma** CD-11-265
- (5) **Icon Bioscience** – various protocols
- (6) **Alcon** – various protocols

COMPANY BOARD OF DIRECTORS

- (1) Member, **Encore Vision, Inc.** 2012-2014

WILLIAM C. STEWART, MD

PUBLICATIONS

TEXTBOOKS:

- (1) Stewart WC, **Clinical Practice of Glaucoma**, Thorofare: SLACK, Inc., 1990.

TEXTBOOK CHAPTERS:

- (1) Stewart WC, Brindley GO, Shields MB. Cyclodestructive Procedures. In: Ritch R, Shields MB, Krupin T (eds). **The Glaucomas** (ed. 2). St. Louis: CV Mosby Co., 1995.
- (2) Berland JE, Powers TP, Saunders RA, Rowe HE, Wilson ME, Stewart WC. Enhancement of Perkins tonometry using an external cobalt blue light source. In: Lennerstrand G (ed). **Update on Strabismus and Pediatric Ophthalmology**. Boca Raton: CRS Press Inc., 1995;9:479-81.
- (3) Stewart WC. Glaucoma: Advances in Medical Management. In: Arshinoff S (ed). **National Ophthalmic Speakers Program Proceedings**. Montreal: Medicöpea, 1997;8-14.
- (4) Stewart WC. New (pending) glaucoma medical therapy. In: Yanoff M, Duker JS (eds). **Ophthalmology**. St. Louis: Mosby, Inc., 2004;1553-6.
- (5) Konstas AGP, Mikropoulos D, Stewart WC. Fixed Combination Therapy in Glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, Crowston JG (eds.) **Glaucoma. Medical Diagnosis and Therapy**. Philadelphia: W.B. Saunders, 2009:565-75.

MONOGRAPHS:

- (1) Castelli WP, Stewart WC. Serum lipids and coronary heart disease: implications for the ophthalmologist. Cosponsored by the Framingham Heart Study and the University of Massachusetts Medical School. OAPI, 1994.
- (2) Stewart WC. Glaucoma: Advances in medical management. National Ophthalmic Speakers Program, 1996.
- (3) Stewart WC. New and current drug therapy for glaucoma. Ciba Clinical Symposium, 1997.
- (4) Stewart WC. Side effects and glaucoma medications. *Atualidade Oftalmica* 1999;2,No. 1.
- (5) Stewart WC. IOP control, neuroprotection and blood flow, putting it all into perspective. *Tough on Pressure*, Pharmacia & Upjohn, Canada 1999;9-25.
- (6) Higginbotham E, Lee DA, Parrish R, Shaya F, Stewart WC. The impact of hyperemia on compliance, costs, and medical practice. *The Ritz-Carlton*, Boston, Massachusetts, June 11, 2004 (*Ophthalmology Times* 2004;29; Supplement 6).

ARTICLES:

- (1) Biehl ER, Stewart WC, Marks A, Reeves PC. Influence of the cyano group on orientation of nucleophiles of aryne. Reaction of isomeric halobenzonitriles with alkali amides in liquid ammonia. **J Org Chem** 1979;44:3672-5.
- (2) Waelterman JM, Cibis GW, Spellman CR, Stewart WC. Racial differences in the cup-to-disc ratios of a normal pediatric population. **Glaucoma** 1986;8:48-51.

WILLIAM C. STEWART, MD

ARTICLES (continued)

- (3) Stewart WC, Shields MB. Use of peripheral visual field screening in glaucoma. **Invest Ophthalmol Vis Sci** 1987;28:S9.
- (4) Reichart R, Stewart WC, Shields MB. Limbus-based versus fornix-based conjunctival flaps in trabeculectomy. **Ophthalmic Surg** 1987;18:672-6.
- (5) Stewart WC, Shields MB, Ollie AR. Peripheral visual field testing by automated kinetic perimetry in glaucoma. **Arch Ophthalmol** 1988;106:202-6.
- (6) Shields S, Stewart WC, Shields MB. Transpupillary argon laser cyclophotocoagulation in the treatment of glaucoma. **Ophthalmic Surg** 1988;19:171-5.
- (7) Stewart WC, Shields MB. Management of anterior chamber depth after trabeculectomy. **Am J Ophthalmol** 1988;106:41-44
- (8) Stewart WC, Shields MB. Reply to management of anterior chamber depth after trabeculectomy letter. **Am J Ophthalmol** 1988;106:508-9.
- (9) Reichert RW, Shields MB, Stewart WC. Intraocular pressure response to replacing pilocarpine with carbachol. **Am J Ophthalmol** 1988;106:747-8.
- (10) Stewart WC, Shields MB. Reply to management of anterior chamber depth after trabeculectomy letter. **Am J Ophthalmol** 1988;106:767-8.
- (11) Stewart WC, Shields MB, Ollie AR. Full threshold versus quantification of defects for visual field testing in glaucoma. **Graefes Arch Clin Exp Ophthalmol** 1989;27:51-4.
- (12) Martone JF, Shields MB, DePaul KL, Ollie AB, Stewart WC. Correlation of subjective nonautomated visual field assessment and Vistech contrast sensitivity findings in glaucomatous, ocular hypertensive and age-related normal eyes. **Invest Ophthalmol Vis Sci Suppl** 1989;30:S177.
- (13) Gilpin LB, Stewart WC, Hunt H, Broom C. Components of fluctuations using different Goldmann spot sizes. **Invest Ophthalmol Vis Sci** 1989;30:S177.
- (14) Stewart WC, Gilpin L, Shields MB, Miller K. Hemianopic offsets in ocular hypertension and glaucoma. **Invest Ophthalmol Vis Sci** 1989;30:S56.
- (15) Crosswell HH, Stewart WC, Cascairo M, Hunt H. Components of fluctuation using different background luminosities. **Invest Ophthalmol Vis Sci** 1990;31:S17.
- (16) Stewart WC, Kulze J, Sutherland S. Factors associated with a learning effect in glaucoma patients using automated perimetry. **Invest Ophthalmol Vis Sci** 1990;31:S15.
- (17) Reynolds M, Stewart WC, Sutherland S. Factors which influence the prevalence of positive catch trials in glaucoma patients. **Graefes Arch Clin Exp Ophthalmol** 1990;28:338-41.
- (18) Gilpin LB, Stewart WC, Shields MB, Miller KN. Hemianopic offsets in the visual field of patients with glaucoma. **Graefes Arch Clin Exp Ophthalmol** 1990;28:450-3.
- (19) Young WO, Stewart WC, Hunt H, Crosswell H. Static threshold variability in the peripheral visual field in normal subjects. **Graefes Arch Clin Exp Ophthalmol** 1990;28:454-7.

ARTICLES (continued)

- (20) Weinreb RN, Caldwell DR, Goode SM, Horwitz BL, Laibovitz R, Shrader CE, Stewart RH, Williams AT. A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. **Am J Ophthalmol** 1990;110:189-92.
- (21) Kulze JC, Stewart WC, Sutherland SE. Factors associated with a learning effect in glaucoma patients using automated perimetry. **Acta Ophthalmol (Copenh)** 1990;68:681-6.
- (22) Gilpin LB, Stewart WC, Hunt HH, Broom CD. Threshold variability using different Goldmann stimulus sizes. **Acta Ophthalmol (Copenh)** 1990;68:674-6.
- (23) Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. **Am J Ophthalmol** 1991;111:51-5.
- (24) Stewart WC, Shields MB, Miller KN, Blasini M, Sutherland SE. Early postoperative prognostic indicator following trabeculectomy. **Ophthalmic Surg** 1991;22:23-6.
- (25) Pennebaker GE, Stewart WC, Stewart JA, Hunt H. The effect of the stimulus presentation interval upon the components of fluctuations in automated perimetry. **Invest Ophthalmol Vis Sci** 1991;32:S1106.
- (26) Legler UFC, Assia EI, Hennis HL, Stewart SC, Apple DJ, Carlson AN. Morphologic and histologic analysis of cyclodestructive procedures in phakic and pseudophakic cadaver eyes. **Invest Ophthalmol Vis Sci** 1991;32:S747.
- (27) Stewart WC. The use of subconjunctival 5-fluorouracil following combined trabeculectomy and cataract extraction. **Invest Ophthalmol Vis Sci** 1991;32:S745.
- (28) McCarty G, Stewart WC, Quayle W, Levin J, Rienhart M. Evaluation of morning IOP control by bedtime pilocarpine gel dosing. **Invest Ophthalmol Vis Sci** 1991;32:946.
- (29) Crosswell HH, Stewart WC, Cascairo MA, Hunt HH. The effect of background intensity on the components of fluctuation as determined by threshold-related automated perimetry. **Graefes Arch Clin Exp Ophthalmol** 1991;229:119-22.
- (30) Hennis HL, Assia E, Stewart WC, Legler UFC, Apple DJ. Transscleral cyclophotocoagulation using a semiconductor diode laser in cadaver eyes. **Ophthalmic Surg** 1991;22:274-8.
- (31) Pennebaker GE, Stewart WC. Response of argon laser trabeculoplasty with varying anterior chamber anatomy. **Ophthalmic Surg** 1991;22:301-2.
- (32) Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT. A three-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. **Graefes Arch Clin Exp Ophthalmol** 1991;229:258-61.
- (33) Stewart WC, Shields MB. The peripheral visual field in glaucoma: reevaluation in the age of automated perimetry. **Surv Ophthalmol** 1991;36:59-69.
- (34) Reynolds M, Stewart WC, Sutherland S. Factors which influence the prevalence of positive catch trials in glaucoma patients. **Ophthalmology Digest** 1991;3:19-20.
- (35) Cascairo MA, Stewart WC, Sutherland SE. Influence of missed catch trials on the visual field in normal subjects. **Graefes Arch Clin Exp Ophthalmol** 1991;229:437-41.

ARTICLES (continued)

- (36) Stewart WC, Cascairo MA, Banta R. The use of a new portable noncontact tonometer in home tonometry. **Ann Ophthalmol** 1991;23:377-82.
- (37) Assia EI, Hennis HL, Stewart WC, Legler UFC, Carlson AN, Apple DJ. Comparison of Nd: YAG and diode transscleral cyclophotocoagulation and cyclocryotherapy. **Invest Ophthalmol Vis Sci** 1991;32:2774-8.
- (38) Pennebaker GE, Stewart WC. Temporal visual field in glaucoma: a re-evaluation in the automated perimetry era. **Graefes Arch Clin Exp Ophthalmol** 1992;230:111-4.
- (39) Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. **Ophthalmology Digest** 1991;4:18-9.
- (40) Pennebaker GE, Stewart WC, Stewart JA, Hunt HH. The effect of stimulus presentation interval upon the components of fluctuation in static automated perimetry. **Eye** 1992;6:353-5.
- (41) Hennis HL, Stewart WC. The use of 5-fluorouracil in patients following combined trabeculectomy and cataract extraction. **Ophthalmic Surg** 1991;22:451-4.
- (42) Stewart WC, Hunt HH. Threshold variation in automated perimetry. **Surv Ophthalmol** 1993;37:353-61.
- (43) Hennis HL, Stewart WC, Neville B, O'Connor KL, Apple DJ. Carcinoma arising in an odontogenic keratocyst with orbital invasion. **Doc Ophthalmol** 1991;77:73-9.
- (44) Stewart WC, Shields MB, Miller KN, Blasini M, Sutherland SE. Early postoperative prognostic indicators following trabeculectomy. **Ophthalmology Digest** 1991;22:23-6.
- (45) Sponsel WE, DePaul KL, Martone JF, Shields MB, Stewart WC. Association of Vistech contrast sensitivity and visual field findings in glaucoma. **Br J Ophthalmol** 1992;75:558-60.
- (46) Hennis HL, Stewart WC. Semiconductor diode laser transscleral cyclophotocoagulation in patients with glaucoma. **Am J Ophthalmol** 1992;113:81-5.
- (47) Stewart WC. Static versus kinetic testing in the nasal peripheral field in patients with glaucoma. **Acta Ophthalmol** 1992;70:79-84.
- (48) Stewart WC, Shields MB, Allen RC, Lewis RA, Cohen JS, Hoskins HD, Hetherington JN, Bahr RL, Noblin JE, Delehanty JT. A three-month comparison of 1% and 2% carteolol and 0.5% timolol in open-angle glaucoma. **Ophthalmology Digest** 1992;18-9.
- (49) Hennis HL, Stewart WC. Use of the argon laser to close filtering bleb leaks. **Graefes Arch Clin Exp Ophthalmol** 1992;230:537-41.
- (50) Stewart WC, Reid KK. Incidence of systemic and ocular disease which may mimic low-tension glaucoma. **J Glaucoma** 1992;1:27-31.
- (51) Cascairo MA, Stewart WC, Sutherland SE. Reply to: Frankhauser F, Response to influence to missed catch trials on the visual field in normal subjects. **Graefes Arch Clin Exp Ophthalmol** 1992;230.
- (52) Hennis HL, Stewart WC, Jeter EK. Infectious disease risks of fibrin glue (letter). **Ophthalmic Surg** 1992;23:640.
- (53) Stewart WC. The 1991 American Glaucoma Society Meeting. 13-14 December, 1991, San Diego, California. **Glaucoma Abstracts International** 1992;3:12-4.

ARTICLES (continued)

- (54) Stewart WC, Beehler CC, McDonald DK, Croyle TA, Ostrov CS, Rosanelli EG, Crandall AS. The efficacy of levobunolol 0.25% BID in patients switched from timolol 0.5% BID therapy. **Invest Ophthalmol Vis Sci** 1992;33:S1122.
- (55) Legler UFC, McMillan TA, Stewart WC, Apple DJ. Morphologic, histologic and electron microscopic comparison of diode and argon laser trabeculoplasty in cadaver eyes. **Invest Ophthalmol Vis Sci** 1992;33:S1159.
- (56) Bluestein EC, Stewart WC. Tight versus loose scleral flap suture closure in trabeculectomy surgery. **Invest Ophthalmol Vis Sci** 1992;33:S1160.
- (57) Reid KK, Stewart WC, Kelly DM. Determining visual potential in patients with total cups from glaucoma undergoing combined trabeculectomy and cataract extraction. **Invest Ophthalmol Vis Sci** 1992;33:S1270.
- (58) Nutaitis MJ, Stewart WC, Kelly DM. Use of the pattern discrimination perimeter in patients with glaucoma and ocular hypertension. **Invest Ophthalmol Vis Sci** 1992;33:S1384.
- (59) Kelly DM, Stewart WC. Long- and short term fluctuation with the pattern discrimination perimeter. **Invest Ophthalmol Vis Sci** 1992;33:S1384.
- (60) Bluestein EC, Stewart WC. Tight versus loose flap closure in trabeculectomy surgery. **Doc Ophthalmol** 1993;84:379-85.
- (61) Nutaitis MJ, Stewart WC, Kelly DM, Hunt HH, Severns ML. Pattern discrimination perimeter testing in glaucoma and ocular hypertensive patients. **Am J Ophthalmol** 1992;114:297-301.
- (62) Stewart WC, Kelly DM, Hunt HH. Long- and short-term fluctuation on the pattern discrimination perimeter. **Am J Ophthalmol** 1992;114:302-6.
- (63) McMillan TA, Stewart WC, Legler UFC, Powers T, Nutaitis MJ, Apple DJ. Comparison of diode and argon laser trabeculoplasty in cadaver eyes. **Invest Ophthalmol Vis Sci** 1994;35:706-10.
- (64) McMillan TA, Stewart WC, Nutaitis MJ, Powers TP, Apple DJ. The effect of varying wavelength on subconjunctival scleral laser suture lysis in rabbits. **Acta Ophthalmol (Copenh)** 1992;70:758-61.
- (65) McMillan TA, Stewart WC, Hunt HH. Association of reliability with reproducibility of the glaucomatous visual field. **Acta Ophthalmol (Copenh)** 1992;70:665-70.
- (66) Stewart WC. Static versus kinetic testing in the nasal peripheral field in patients with glaucoma. **Ophthalmology Digest** 1992 Dec;6-7.
- (67) Beehler CC, Stewart WC, MacDonald DK, Croyle TA, Ostrov CS, Rosanelli EG, Crandall AS, Iacono TL, Lue JC, Kelley EP. A comparison of the ocular hypotensive efficacy of twice-daily 0.25% levobunolol to 0.5% timolol in patients previously treated with 0.5% timolol. **J Glaucoma** 1992;1:237-42.
- (68) McMillan TA, Stewart WC, Hennis HL, Hunt HH, Apple DJ. Histologic differences in the conjunctiva between black and white glaucoma patients. **Ophthalmic Surg** 1992;23:762-5.
- (69) Hawkins TA, Stewart WC. One year results of semiconductor transscleral cyclophotocoagulation in glaucoma patients. **Arch Ophthalmol** 1993;111:488-91.
- (70) McMillan TA, Stewart WC, Hennis HL, Gwynn DR. The association of conjunctival inflammatory cells with the results of combined cataract extraction and filtration surgery. **J Glaucoma** 1993;2:193-9.

ARTICLES (continued)

- (71) Stewart WC, Reid KK, Pitts RA. The results of trabeculectomy surgery in African-American versus white glaucoma patients. **J Glaucoma** 1993;2:236-40.
- (72) Gwynn DR, Stewart WC, Hennis HL, McMillan TA, Pitts RA. Association of conjunctival structure and inflammatory cell count to the results of trabeculectomy surgery in primary open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1993;34:S724.
- (73) Stewart WC, Gwynn DR, Hennis HL, McMillan TA, Pitts RA. The influence of age upon the inflammatory cell counts and structure of conjunctiva in chronic open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1993;34:S724.
- (74) Bluestein EC, Stewart WC. Comparison of single-plate Molteno implantation versus trabeculectomy with 5-fluorouracil in glaucoma patients at high risk for failure with filtration surgery. **Invest Ophthalmol Vis Sci** 1993;34:S731.
- (75) Chorak RP, Stewart WC. Scotopic vision testing in patients with ocular hypertension and glaucoma. **Invest Ophthalmol Vis Sci** 1993;34:S1269.
- (76) Daroff RB, Frishman WH, Lederman RJ, Stewart WC. Beta-blockers: beyond cardiology. **Patient Care** 1993;27:47-70.
- (77) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. **Am J Ophthalmol** 1993;116:176-81.
- (78) Hawkins TA, Stewart WC. One-year results of semiconductor transscleral cyclophotocoagulation in patients with glaucoma. **Ophthalmology Digest** 1993:9-10.
- (79) Stewart WC. Avoiding mistakes in interpreting visual fields, Part I: basic concepts. **Clinical Signs in Ophthalmology** 1993;14:1-14.
- (80) Bluestein EC, Stewart WC. Trabeculectomy with 5-fluorouracil versus single-plate Molteno implantation. **Ophthalmic Surg** 1993;24:669-73.
- (81) Gwynn DR, Stewart WC, Pitts RA, McMillan TA, Hennis HL. Conjunctival structure and cell counts and the results of filtration surgery. **Am J Ophthalmol** 1993;116:464-8.
- (82) Stewart WC, Hunt HH. Threshold variation in automated perimetry (abstract). **Am J Ophthalmol** 1993;116:122.
- (83) Gwynn DR, Stewart WC, Hennis HL, McMillan TA, Pitts RA. The influence of age upon inflammatory cell counts and structure of conjunctiva in chronic open-angle glaucoma. **Acta Ophthalmol (Copenh)** 1993;71:691-5.
- (84) Stewart WC, Connor AB, Hunt HH. Prediction of postoperative visual acuity in patients with total glaucomatous cupping using the Potential Acuity Meter and automated perimetry. **Ophthalmic Surg** 1993;24:730-4.
- (85) Fechtner RD, Zimmerman TJ, Katz LJ, Layden WE, Stewart WC, Wise JB. Clinical consultation. **Ophthalmic Practice** 1993;11:259-63.
- (86) Stewart WC, Crinkley CMC, Murrell HP. Cigarette smoking history in normals, ocular hypertensives and chronic open-angle glaucoma patients (letter). **Am J Ophthalmol** 1994;117:267-8.
- (87) Stewart WC, Pitts RA. Postoperative prognostic indicators following trabeculectomy. **Acta Ophthalmol (Copenh)** 1993;71:733-8.

ARTICLES (continued)

- (88) Stewart WC. Avoiding mistakes in interpreting visual fields, Part II: Evaluating the printout. **Clinical Signs in Ophthalmology** 1993;14:1-12.
- (89) Gwin TD, Stewart WC, Gwynn DR. Filtration surgery in rabbits treated with diclofenac or prednisolone acetate. **Ophthalmic Surg** 1994;25:245-50.
- (90) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. **Am J Ophthalmol** 1993;116:176-81.
- (91) Stewart WC, Connor AB, Pitts RA. Prognostic factors and postoperative course following single-plate Molteno implantation. **Doc Ophthalmol** 1994;86:409-17.
- (92) Carlson AN, Stewart WC, Tso PC. Intraocular lens complications requiring removal or exchange. **Surv Ophthalmol** 1998;42:417-40.
- (93) Stroman GA, Stewart WC, Golnik KC, Curé JA, Olinger R. Evaluation of magnetic resonance imaging in patients with low tension glaucoma. **Invest Ophthalmol Vis Sci** 1994;35:S1255.
- (94) Thompson TL, Hamzavi S, Stewart WC. Use of diagnostic ultrasound in assisting placement of diode transscleral cyclophotocoagulation applications. **Invest Ophthalmol Vis Sci** 1994;35:S2172.
- (95) Connor AB, Stewart WC, Stroman GA. Optic nerve head characteristics in patients with progressed or stable ocular hypertension. **Invest Ophthalmol Vis Sci** 1994;35:S1843.
- (96) Odom MD, Stewart WC, Stroman GA. Differences in optic nerve head findings in patients with low-tension glaucoma with or without neurosyphilis. **Invest Ophthalmol Vis Sci** 1994;35:S1843.
- (97) Power TP, Stewart WC, Stroman GA. Ultrastructural characteristics of filtration blebs. **Invest Ophthalmol Vis Sci** 1994;35:S1421.
- (98) Hamzavi S, Stewart WC, Thompson TL. Inter- and intraobserver variation of the optic nerve head in cadaver eyes using the glaucoma-scope. **Invest Ophthalmol Vis Sci** 1994;35:S1347.
- (99) Stewart WC, Ritch R, Shin D, McCarty G, Rinehart M, Silver L, DeFaller J, Godio L. A double-masked, three month comparison of the additivity of 0.5% and 1.0% apraclonidine to timolol. **Invest Ophthalmol Vis Sci** 1994;35:S2176.
- (100) Stewart WC. Carteolol, an ophthalmic β -adrenergic blocker with intrinsic sympathomimetic activity. **J Glaucoma** 1994;3:339-45.
- (101) Stewart WC, Chauhan BC. Newer visual function techniques in the evaluation of glaucoma. **Surv Ophthalmol** 1995;40:119-35.
- (102) Stewart WC, Sorrow NA. Evaluation of noninvasive carotid studies in patients with low-tension glaucoma (letter). **Acta Ophthalmol (Copenh)** 1994;72:398.
- (103) Stewart WC, Crinkley CMC. Influence of serous suprachoroidal detachments on the results of trabeculectomy surgery. **Acta Ophthalmol (Copenh)** 1994;72:309-14.
- (104) Nutaitis MJ, Stewart WC, Kelly DM. Musterunterscheidungsperimetrie bei Patienten mit Glaukom und okulärer Hypertension. **Search on Glaucoma** 1994;2:99.
- (105) Stewart WC, Reid KK, Pitts RA. The results of trabeculectomy surgery in African-American versus white glaucoma patients (abstract). **Am J Ophthalmol** 1994;117:552.

ARTICLES (continued)

- (106) Stewart WC, Chorak RP, Murrell HP. Evaluation of the whole-field scotopic retinal sensitivity tester in clinical glaucoma practice. **J Glaucoma** 1994;3:280-85.
- (107) Hamzavi R, Stewart WC, Thompson TL. Use of diagnostic ultrasound in placing diode transscleral cyclophotocoagulation applications (letter). **Am J Ophthalmol** 1994;118:667-8.
- (108) Hawkins TA, Stewart WC, McMillan TA, Gwynn DR. Analysis of diode, argon, and Nd:YAG peripheral iridectomy in cadaver eyes. **Doc Ophthalmol** 1994;87:367-76.
- (109) Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, Van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. **Arch Ophthalmol** 1995;113:287-92.
- (110) Stewart WC, Crinkley CMC, Carlson AN. Results of trabeculectomy combined with phacoemulsification versus trabeculectomy combined with extracapsular cataract extraction in patients with advanced glaucoma. **Ophthalmic Surg** 1994;25:621-7.
- (111) Stewart WC. The effect of lifestyle on the relative risk to develop open-angle glaucoma. **Current Opin Ophthalmol** 1995;6:3-9.
- (112) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. **Arch Ophthalmol** 1995;113:168-72.
- (113) Stewart WC, Konstas AGP. The diagnosis and treatment of glaucoma suspects. **Ophthalmologica** 1994;6:410-18.
- (114) Stewart WC, Crinkley CMC, Carlson AN. Fornix- vs. limbus-based flaps in combined phacoemulsification and trabeculectomy. **Doc Ophthalmol** 1994;88:141-51.
- (115) Hamzavi S, Stewart WC, Jackson G, Thompson TL. Reproducibility of the Glaucoma-scope in cadaver eyes. **Acta Ophthalmol Scand** 1995;75:264-7.
- (116) Stewart WC, Crinkley CMC, Carlson AN. Results of combined phacoemulsification and trabeculectomy in patients with elevated preoperative intraocular pressures. **J Glaucoma** 1995;4:164-9
- (117) Jackson GJ, Wang X-H, Stewart WC. Differences in optic disc in LTG patients with relatively low or high pressures. **Invest Ophthalmol Vis Sci** 1995;36:S78.
- (118) Blessing WD, Detkova D, Stewart WC, Stroman GA. Evaluation of short-term fluctuation in pattern discrimination perimetry. **Invest Ophthalmol Vis Sci** 1995;36:S337.
- (119) Rogers GM, Stewart WC, Crinkley CMC, Carlson AN. Effect of cataract extraction on automated fields in chronic open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1995;36:S339.
- (120) Powers TP, Stroman GA, Stewart WC, Wang X-H, Hamzavi S. Use of indocyanine green to enhance the effect of diode transscleral cyclophotocoagulation in a cadaver eye model. **Invest Ophthalmol Vis Sci** 1995;36:S556.
- (121) Stroman GA, Hamzavi S, Stewart WC, Blessing WD, Powers T. Comparison of contact transscleral semiconductor diode laser cyclophotocoagulation versus non-contact technique in cadaver eyes. **Invest Ophthalmol Vis Sci** 1995;36:S559.
- (122) Stewart JA, Stroman GA, Stewart WC. Safety of the washout period of β -adrenergic blockers used in clinical trials. **Invest Ophthalmol Vis Sci** 1995;36:S737.

ARTICLES (continued)

- (123) Scafidi AF, Stewart WC, Ropo AM and Timolol Hemihydrate Study Group. Safety and efficacy of timolol hemihydrate 0.25 and 0.5% ophthalmic solution in open-angle glaucoma and ocular hypertension. **Invest Ophthalmol Vis Sci** 1995;36:S737.
- (124) Stewart WC, Ritch R, Laibovitz R, McCarty G, Silver L, DeFaller J. A double-masked, 90 day study of the efficacy of 0.25% and 0.5% apraclonidine versus timolol. **Invest Ophthalmol Vis Sci** 1995;36:S738.
- (125) Marotto Me, Hamzavi S, Stewart WC, Stroman GA, Wang X-H, Powers TP, Rogers GM, Greene WB. Morphologic changes in the trabecular meshwork following phacoemulsification in a cadaver eye model. **Invest Ophthalmol Vis Sci** 1995;36:S730.
- (126) Hamzavi S, Stewart WC, Stroman GA, Blessing WD. Accuracy model for Glaucoma-Scope optic nerve head topographical measurements. **Invest Ophthalmol Vis Sci** 1995;36:S970.
- (127) Stewart WC, Hamzavi S, Stroman GA. Evaluating the accuracy of digitalized retinal images using laser induced changes to the optic disc in a cadaver eye model. **Invest Ophthalmol Vis Sci** 1995;36:S971.
- (128) Stewart WC, Connor AB, Wang X-H. Anatomic features of the optic disc and risk of progression in ocular hypertension. **Acta Ophthalmol Scand** 1995;73:237-41.
- (129) Stewart WC, Rogers GM, Crinkley CMC, Carlson AN. Effect of cataract extraction on automated fields in chronic open-angle glaucoma. **Arch Ophthalmol** 1995;113:875-9.
- (130) Stewart WC. Megatrends in glaucoma meds. **Review Ophthalmol** 1995;79-83.
- (131) Stewart WC, Connor AB, Rogers GM. Correlation of pattern discrimination perimetry to the optic disc and visual field in ocular hypertensive and chronic open-angle glaucoma patients. **Int Ophthalmol** 1995;19:101-7.
- (132) Stewart WC, Crinkley CMC, Carlson AN. Fornix- vs. limbus-based flaps in combined phacoemulsification and trabeculectomy. **Ophthalmology Digest** 1995;27-8.
- (133) Stroman GA, Stewart WC, Golnik KC. Magnetic resonance imaging in patients with low-tension glaucoma - in reply. **Arch Ophthalmol** 1996;114:105.
- (134) Stroman GA, Stewart WC. Magnetic resonance imaging in patients with low-tension glaucoma - in reply. **Arch Ophthalmol** 1995;113:1229
- (135) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RE. Magnetic resonance imaging in patients with low-tension glaucoma. **Year Book of Ophthalmology** 1996.
- (136) Stroman GA, Stewart WC, Wang X-H, Hamzavi S, Powers TP. Use of ICG with diode transscleral cyclophotocoagulation in a cadaver eye model. **Ophthalmic Surg Lasers** 1995;26:582-3.
- (137) Stewart WC, Crinkley CMC, Carlson AN. Prognostic factors in long-term intraocular pressure control following combined phacoemulsification and trabeculectomy. **Acta Ophthalmol Scand** 1996;74:145-50.
- (138) Stewart WC. Discussion of Cases in Controversy. **J Glaucoma** 1995.
- (139) Stewart WC. Timolol hemihydrate - a new formulation of timolol for the treatment of glaucoma. **J Ocul Pharmacol Ther** 1996;12:225-37.
- (140) Stroman GA, Stewart WC, Hamzavi S, Powers TP, Blessing WD. Contact versus non-contact diode transscleral cyclophotocoagulation in cadaver eyes. **Ophthalmic Surg Lasers** 1996;27:60-5.

ARTICLES (continued)

- (141) Powers TP, Stewart WC, Stroman GA. Ultra structural features of filtration blebs with different clinical appearances. **Ophthalmic Surg Lasers** 1996;27:790-4.
- (142) Wang X-H, Stewart WC, Jackson GJ. Differences in optic discs in low-tension glaucoma patients with relatively low or high pressures. **Acta Ophthalmol Scand** 1996;74:364-7.
- (143) Stewart WC, Castelli WP. Systemic side effects of topical β -adrenergic blockers. **Clin Cardiol** 1996;19:691-7.
- (144) Stewart WC, Odom MB, Stroman GA. The optic disc in low-tension glaucoma patients with or without positive syphilis serology. **Ann Ophthalmol Glaucoma** 1996.
- (145) Stewart WC, Chorak RP, Murrell HP. Evaluation of the whole-field scotopic retinal sensitivity tester in clinical glaucoma practice. **Search on Glaucoma** 1996.
- (146) Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. **Search on Glaucoma** 1996.
- (147) Stewart WC. New Glaucoma Medicines: Update 1996. **Review Ophthalmol** 1996;74-9.
- (148) Stewart WC. Effects and side effects of apraclonidine. **Klin Monatsbl Augenheilkd** 1996;209:A7-13.
- (149) Dubiner HB, Hill R, Kaufman H, Keates EU, Zimmerman TJ, Mandell AI, Mundorf TK, Bahr RL, Schwartz LW, Towey AW, Hurvitz LM, Starita RJ, Sassani JW, Ropo A, Gunn R, Stewart WC. Timolol hemihydrate vs. timolol maleate in ocular hypertension and open-angle glaucoma. **Am J Ophthalmol** 1996;121:522-8.
- (150) Stewart WC. Prostaglandin analogues: their usage and benefits in glaucoma treatment. **Ophthalmic Practice** 1996;14:48-55.
- (151) Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M, and the Apraclonidine Primary Therapy Study Group. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs. 0.5% timolol. **Arch Ophthalmol** 1996;114:938-42.
- (152) Stewart WC, Chauhan BC. Newer visual function tests in the evaluation of glaucoma (abstract). **Am J Ophthalmol** 1996;121:235.
- (153) Konstas AGP, Mantziris DA, Stewart WC. Comparison of IOP diurnal variation in newly diagnosed, untreated patients with exfoliation glaucoma and POAG. **Invest Ophthalmol Vis Sci** 1996;37:S821.
- (154) Hamzavi S, Stewart WC, Hamzavi SL, Stroman GL. Transcranial Doppler in progressed and stable ocular hypertensive patients. **Invest Ophthalmol Vis Sci** 1996;37:S31.
- (155) Jiang WJ, Ma JX, Stewart WC. Binding of timolol to ocular tissues in not though β -adrenergic receptor. **Invest Ophthalmol Vis Sci** 1996;37:S836.
- (156) LoPresto C, Ragaiey T, Ma JX, Stewart WC. Optic nerve axon loss in superglue induced IOP elevation in rats. **Invest Ophthalmol Vis Sci** 1996;37:S830.
- (157) Sine C, Stewart WC. Long term follow-up of IOP control in glaucoma patients stabilized on Iopidine® for at least six months. **Invest Ophthalmol Vis Sci** 1996;37:S1102.
- (158) Stewart JA, Stewart WC, Sutherland C, Sine CS. Cholesterol as a risk factor for elevated IOP. **Invest Ophthalmol Vis Sci** 1996;37:S814.

ARTICLES (continued)

- (159) Stroman GA, LoPresto C, Stewart WC, Kent DG, Greene WB. Trabecular meshwork changes occurring with phacoemulsification in canine eyes. **Invest Ophthalmol Vis Sci** 1996;37:S824.
- (160) Ragaiey T, Ma JX, Seigel GM, Jiang WJ, Stewart WC. L-deprenyl increases the survival of retinal neuronal cell line E1A-NR3 dying by apoptosis. **Invest Ophthalmol Vis Sci** 1996;37:S830.
- (161) Stewart WC, Konstas AGP, Stroman GA, Sine CS. Clinical presentation of glaucoma in patients with exfoliation glaucoma versus POAG. **Invest Ophthalmol Vis Sci** 1996;37:S821.
- (162) Darby WF, Kent AR, Stewart WC. Comparison of optic nerve head findings and ischemic lesions in low-tension glaucoma patients. **Invest Ophthalmol Vis Sci** 1996;37:S29.
- (163) Stewart WC, Sine CS, Carlson AN. Three-millimeter versus six-millimeter incisions in combined phacoemulsification and trabeculectomy. **Ophthalmic Surg Lasers** 1996;27:832-8.
- (164) Stroman GA, Stewart WC, Golnik KC, Curé JK, Olinger RD. Magnetic resonance imaging in patients with low-tension glaucoma. **Arch Ophthalmol (India)** 1996;3:192-6.
- (165) Golnik KC, Hund PW, Stroman GA, Stewart WC. Magnetic resonance imaging in patients with unexplained optic neuropathy. **Ophthalmology** 1996;103:515-20.
- (166) Konstas AGP, Mantziris DA, Stewart WC. IOP diurnal curve in newly diagnosed patients with exfoliation glaucoma and primary open-angle glaucoma. **Ophthalmologica (Greece)** 1996;8:32-8.
- (167) Stewart WC, Sine C, Sutherland S, Stewart JA. Total cholesterol and high density lipoprotein as risk factors for increased intraocular pressure. **Am J Ophthalmol** 1996;122:575-7.
- (168) Stewart WC, Sine CS, LoPresto C. Surgical versus medical management of chronic open-angle glaucoma. **Am J Ophthalmol** 1996;122:767-74.
- (169) Konstas AGP, Mantziris DA, Stewart WC. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. **Arch Ophthalmol** 1997;115:182-5.
- (170) Konstas AGP, Stewart WC, Stroman GA, Sine CS. Clinical presentation and initial treatment patterns in patients with exfoliation glaucoma versus primary open-angle glaucoma. **Ophthalmic Surg Lasers** 1997;28:111-7.
- (171) Stroman GA, Stewart WC, Stewart JA. Safety of β -adrenergic blocker washout period in clinical trials. **Acta Ophthalmol Scand** 1997;75:94-5.
- (172) Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE, Van Buskirk EM. The efficacy of apraclonidine as an adjunct to timolol therapy. **Search on Glaucoma** 1996;4:96.
- (173) Stewart WC. Chronic open-angle glaucoma and lifestyle. **Prog Retin Eye Res** 1997;16:567-90.
- (174) Stewart WC, Garrison P. Glaucoma treatment comes of age: New approaches in primary care. **Review Ophthalmol** 1997 March;119-22.
- (175) Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL, and the NIGHT study group. Cardiovascular effects of topical carteolol and timolol in patients with ocular hypertension and primary open-angle glaucoma. **Am J Ophthalmol** 1997;123:465-77.
- (176) Stewart WC, Sine C, Cate E, Minno GE, Hunt HH. Daily cost of β -adrenergic blocker therapy. **Arch Ophthalmol** 1997;115:853-6.

ARTICLES (continued)

- (177) Ragaiey T, Ma J-X, Jiang W-J, Greene W, Seigel GM, Stewart WC. L-deprenyl protects injured retinal precursor cells in vitro. **J Ocular Pharmacol Ther** 1997;13:479-88.
- (178) Stewart WC, Sine C. Reply to letter to editor regarding: Surgical versus medical management of chronic open-angle glaucoma. **Am J Ophthalmol** 1997;123:860-2.
- (179) Stewart JA, Kent AR, Dubiner HB, Whitaker R, Mundorf TK, Stewart WC. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-c. **Invest Ophthalmol Vis Sci** 1997;38:S1295.
- (180) Sine CS, Stewart WC, Stewart JA, Solomon KD. Changes in corneal analysis following phacoemulsification and posterior chamber lens insertion. **Invest Ophthalmol Vis Sci** 1997;38:S3984.
- (181) Mundorf TK, Sine CS, Otero D, Stewart JA, Stewart WC. Safety and efficacy of switching timolol maleate solution to timolol hemihydrate (Betimol™) 0.5% given twice daily. **Invest Ophthalmol Vis Sci** 1997;38:S2594.
- (182) Mantziris DA, Konstas AGP, Maltezos A, Stewart WC. Diurnal variation of intraocular pressure in exfoliation or primary open-angle glaucoma patients treated with timolol 0.5% and timolol gel forming ophthalmic solution. **Invest Ophthalmol Vis Sci** 1997;38:S2593.
- (183) Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Diurnal variation of intraocular pressure in patients with exfoliation glaucoma or primary open-angle glaucoma treated with timolol 0.5%. **Invest Ophthalmol Vis Sci** 1997;38:S2592.
- (184) Solomon KD, Stewart WC, Hunt HH, Cate EA. Intracameral carbachol 0.01% in phacoemulsification and posterior chamber lens implantation. **Invest Ophthalmol Vis Sci** 1997;38:S1297.
- (185) Gasper JR, Stewart JA, Leland T, Stewart WC. Efficacy and safety of Betimol™ (timolol hemihydrate solution) given once daily versus Timoptic-XE™ given once daily in the treatment of elevated intraocular pressure. **Invest Ophthalmol Vis Sci** 1997;38:S2590.
- (186) Laibovitz RA, Dubiner HB, Sall KN, Mundorf TK, Katz LJ, Singh K, Shulman DG, Siegel LI, Nussbaum LL, Stewart WC. Ocular tolerability and intraocular pressure effects of carteolol and timolol in older women with ocular hypertension or primary open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1997;38:S2586.
- (187) Pruitt CA, Stewart WC, Solomon KD. Changes in visual fields following phacoemulsification and posterior chamber IOL insertion. **Invest Ophthalmol Vis Sci** 1997;38:S2641.
- (188) Cate EA, Stewart WC, Sine CS, Minno GE, Hunt HH. Daily cost of β -adrenergic blocker therapy. **Invest Ophthalmol Vis Sci** 1997;38:S2585.
- (189) Stewart WC, Dubiner HB, Laibovitz RA, Sall KN, Mundorf TK, Katz LJ, Singh K, Shulman DG, Siegel LI, Nussbaum LL. The effect of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1997;38:S2591.
- (190) Konstas AGP, Mantziris DA, Cate EA, Stewart WC. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. **Arch Ophthalmol** 1997;115:975-9.
- (191) Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL and the Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Efficacy of carteolol 1% versus timolol maleate 0.5% in patients with increased intraocular pressure. **Am J Ophthalmol** 1997;124:498-505.

ARTICLES (continued)

- (192) Solomon KD, Stewart WC, Hunt HH, Cate EA. Intracameral carbachol 0.01% in phacoemulsification and posterior chamber lens implantation. **Am J Ophthalmol** 1998;125:36-43.
- (193) Stewart WC, Garrison PM. β -blocker-induced complications and the glaucoma patient: newer treatments to help reduce systemic side effects. **Arch Intern Med** 1998;158:221-6.
- (194) Stewart WC. Case reports. **Review Ophthalmol** 1997;6:50-4.
- (195) Mundorf TK, Cate EA, Sine CS, Otero DW, Stewart JA, Stewart WC. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. **J Ocular Pharmacol Ther** 1998;14:129-35.
- (196) Stewart WC. When to switch patients to one of the new glaucoma medications. **Review Ophthalmol** 1998;76-82.
- (197) Stewart WC. Towards a new blood flow product. **Review Ophthalmol** 1998;137-40.
- (198) Kent AR, Dubiner HB, Whitaker R, Mundorf TK, Stewart JA, Cate EA, Stewart WC. The efficacy and safety of diclofenac 0.1% versus prednisolone acetate 1% following trabeculectomy with adjunctive mitomycin-C. **Ophthalmic Surg Lasers** 1998;29:562-9.
- (199) Stewart WC, Pruitt CA, Cate EA, Bean GW. Ophthalmologists' treatment practices regarding elevated intraocular pressure. **Invest Ophthalmol Vis Sci** 1998;38:S33.
- (200) Louden TA, Smith SL, Pruitt CA, Sine CS, Stewart WC. The use of latanoprost 0.05% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. **Invest Ophthalmol Vis Sci** 1998;39:S256.
- (201) Clifford TB, Smith SL, Sine CS, Pruitt CA, Hudgins AC, Stewart WC. The use of latanoprost 0.05% once daily to reduce the intraocular pressure in patients with uveitis. **Invest Ophthalmol Vis Sci** 1998;38:S256.
- (202) Seabrook CD, Smith SL, Sine SL, Pruitt CA, Stewart WC. The influence of latanoprost 0.005% once daily as primary or adjunctive therapy on intraocular pressure. **Invest Ophthalmol Vis Sci** 1998;39:S257.
- (203) Stewart JA, Koester J, Kapik B, Pugh S, Stewart WC. The IOP diurnal curve in COAG or OHT patients treated with Rescula® 0.12% or timolol maleate 0.5%. **Invest Ophthalmol Vis Sci** 1998;39:S481.
- (204) Konstas AGP, Maltezos A, Bufidis T, Hudgins AC, Stewart WC. 24 hour control of IOP with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1998;39:S708.
- (205) Hudgins AC, Pruitt CA, Sine CS, Stewart JA, Stewart WC. Drop characteristics of latanoprost, brimonidine, apraclonidine, dorzolamide, timolol solution and Timoptic-XE®. **Invest Ophthalmol Vis Sci** 1998;39:S709.
- (206) Stewart WC, Osterman J. Serum lipid physiology and the influence of glaucoma medications. **Surv Ophthalmol** 1998;43:233-44.
- (207) Smith SL, Sine CS, Pruitt CA, Stewart WC. The use of latanoprost 0.005% once daily and its effect on intraocular pressure as primary or adjunctive therapy. **J Ocular Pharmacol Ther** 1999;15:29-39.
- (208) Stewart WC, Stewart JA, Kapik BM. The effect of unoprostone isopropylate 0.12% vs. timolol maleate 0.5% on the diurnal IOP. **J Glaucoma** 1998;6:388-97.

ARTICLES (continued)

- (209) Stewart WC, Leland TM, Cate EA, Stewart JA. Efficacy and safety of timolol solution once daily vs. timolol gel in treating elevated IOP. **J Glaucoma** 1998;7:402-47.
- (210) Stewart WC. New perspectives in the medical treatment of glaucoma. **Current Opin Ophthalmol** 1999;10:99-108.
- (211) Stewart WC, Dubiner HB, Mundorf TK, Laibovitz RA, Sall KN, Katz LJ, Singh K, Shulman DG, Siegel LI, Hudgins AC, Nussbaum L, Apostolaros M. Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. **Am J Ophthalmol** 1999;127:142-7.
- (212) Stewart WC, Cate EA, Stewart JA. Systemic β -blockade with once daily Betimol or Timoptic-XE. **J Ocular Pharmacol Ther** 1999;15:225-31.
- (213) Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. **Acta Ophthalmol Scand** 1999;77:189-92.
- (214) Stewart WC. Current trends in stepwise therapy. **Review Ophthalmol** 1999;60-4.
- (215) Camras CB, Wax MB, Ritch R, Weinreb R, Robin AI, Higginbotham EJ, Lustgarten J, Stewart WC, Sherwood M, Krupin T, Wilensky J, Cioffi GA, Katz LJ, Schumer RA, Kaufman PL, Minckler D, Zimmerman T, Stjerschantz J, and the United States Latanoprost Study Group. Latanoprost treatment for glaucoma: Effects of treating for 1 year and of switching from timolol. **Am J Ophthalmol** 1998;126:390-9.
- (216) Konstas AGP, Maltezos A, Mantziris DA, Sine CS, Stewart WC. The comparative ocular hypotensive effect of apraclonidine with timolol maleate in exfoliation versus primary open-angle glaucoma patients. **Eye** 1999;13:314-8.
- (217) Holmes KT, Sharpe ED, Day DC, Dubiner H, Stewart WC. Efficacy and safety of timolol hemihydrate 0.5% solution once daily versus timolol maleate gel 0.5% once daily added to latanoprost 0.005%. **Invest Ophthalmol Vis Sci** 1999;40:S664.
- (218) Stewart WC, Halper LK, Najarian D, Johnson-Pratt L, Hartenbaum D. Tolerability and efficacy of dorzolamide versus acetazolamide in patients with ocular hypertension or open-angle glaucoma. **Invest Ophthalmol Vis Sci** 1999;40:S513.
- (219) Leech JN, Sharpe ED, Lee WH, Kolker AE, Day DG, Stewart WC. Latanoprost, brimonidine and dorzolamide used as adjunctive therapy added to β -blocker therapy in ocular hypotensive and primary open-angle glaucoma patients. **Invest Ophthalmol Vis Sci** 1999;40:S665.
- (220) Schuhr J, Neubert B, Harris J, Kaye B, Stewart WC. Benefit of an educational program on disease awareness and compliance in patients with glaucoma. **Invest Ophthalmol Vis Sci** 1999;40:S195.
- (221) Konstas AGP, Mantziris DA, Maltezos A, Cate EA, Stewart WC. Comparison of 24 hour control with timoptic® 0.5% and timoptic-XE™ 0.5% in exfoliation and primary open-angle glaucoma. **Acta Ophthalmol Scand** 1999;77:541-3.
- (222) Stewart WC, Hudgins AC, Pruitt CA, Sine C. Daily cost of newer glaucoma agents. **J Ocul Pharmacol Ther** 1999;15:379-88.
- (223) Konstas AGP, Maltezos AC, Gandi S, Hudgins AC, Stewart WC. Comparison of the 24 hour intraocular pressure reduction with two dosing regimes of latanoprost and timolol in patients with open-angle glaucoma. **Am J Ophthalmol** 1999;128:15-20.

ARTICLES (continued)

- (224) Stewart WC. Glaucoma Medications and their side effects. **Ophthalmic Practice** 1999;17:2.
- (225) Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. **Acta Ophthalmol Scand** 1999;77:668-72.
- (226) Stewart WC, Day DG, Sharpe ED, Dubiner HB, Holmes KT, Stewart JA. Efficacy and safety of timolol solution once daily vs. timolol gel added to latanoprost. **Am J Ophthalmol** 1999;128:692-6.
- (227) Stewart WC, Sharpe ED, Day DG, Kolker AE, Konstas AGP, Lee WH, Reiser JC, Chopra H, Holmes KT. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical α -adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. **J Ocul Pharmacol Ther** 2000;16:251-9.
- (228) Konstas AGP, Maltezos A, Bufidis T, Hudgins AC, Stewart WC. 24 hour control of IOP with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma. **Eye** 2000;14:73-7.
- (229) Stewart WC, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT, Stewart JA. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce the intraocular pressure. **Am J Ophthalmol** 2000;129:723-7.
- (230) Stewart WC, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, Johnson M, Cantrell JB. Factors associated with long-term progression or stability in primary open-angle glaucoma. **Am J Ophthalmol** 2000;130:274-9.
- (231) Konstas AGP, Lake S, Maltezos T, Holmes KT, Stewart WC. Latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. **Invest Ophthalmol Vis Sci** 2000;41:S514.
- (232) Albritton AE, Sharpe ED, Harbin TS, Pastor SA, Day DG, Holmes KT, Stewart JA, Stewart WC. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. **Invest Ophthalmol Vis Sci** 2000;41:S514.
- (233) Stewart JA, Stewart WC, Crockett S, Peloso C, Brown A, Zhu HJ, Shams N. Effect of unoprostone isopropyl 0.15% or timolol maleate 0.5% ophthalmic solutions versus placebo on cardiovascular function in healthy subjects. **Invest Ophthalmol Vis Sci** 2000;41:S514.
- (234) Lindsay CL, Stewart JA, Day DG, Holmes KT, Stewart WC. The effect of timolol maleate 0.5% gel and timolol maleate 0.5% solution twice daily versus placebo on pulmonary function in older primary open-angle glaucoma or ocular hypertensive patients. **Invest Ophthalmol Vis Sci** 2000;41:S515.
- (235) Stewart WC, Walters TR, Day, DG, Evans RM, Friedlaender MH, Chen CE. Effects of ISV-205 (diclofenac in DuraSite®) on corticosteroid-induced IOP response in glaucoma relatives. **Invest Ophthalmol Vis Sci** 2000;41:S51.
- (236) Johnson MA, Kolker AE, Sharpe ED, Day DG, Holmes KT, Leech JN, Cantrell JB, Stewart WC. Factors associated with long-term progression or stability in primary open-angle glaucoma. **Invest Ophthalmol Vis Sci** 2000;41:S518.
- (237) Dirks M, DuBiner H, Cooke D, Stewart W, Drain C, Felix C, VanDenburgh A. Efficacy and safety of the ocular hypotensive lipid AGN-192024 in patients with elevated IOP: A comparison with latanoprost. **Invest Ophthalmol Vis Sci** 2000;41:S514.

ARTICLES (continued)

- (238) Small DS, Acheampong A, Reis B, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L, Tang-Liu D. Blood concentrations of cyclosporin A (CsA) during twice-daily treatment of 0.05% and 0.1% cyclosporine ophthalmic emulsions in patients with moderate to severe keratoconjunctivitis sicca. **Invest Ophthalmol Vis Sci** 2000;41:S359.
- (239) Stewart WC, Day DG, Stewart JA, Holmes KT, Leech JN, Rowan CT, Schwartz GF. Therapeutic success of Latanoprost 0.005% compared to Brimonidine 0.2% in Patients with Open-Angle Glaucoma or Ocular Hypertension. **J Ocul Pharmacol Ther** 2000;16:557-64.
- (240) Lee DA, Fechtner RD, Fiscella RG, Singh K, Stewart WC. Emerging perspectives on glaucoma: highlights of a roundtable discussion. **Am J Ophthalmol** 2000;130:S1-11.
- (241) Stewart WC. Survey Assesses How US Physicians Treat Glaucoma. **Review Ophthalmol** 2001:64-8.
- (242) Netland P, Stewart WC. Glaucoma drugs: safer, more powerful and more to come (Review). **Review Ophthalmol** 2000:41-50.
- (243) Stewart WC, Stewart JA, Holmes KT, Leech JN. Differences in ocular surface irritation between timolol hemihydrate and maleate. **Am J Ophthalmol** 2000;130:712-6.
- (244) Stewart WC. Four ways to make visual field exams more accurate. Here's how to use this in-office consultant better. **Review Ophthalmol** 2000;7:48.
- (245) Konstas AGP, Lake S, Maltezos AC, Holmes KT, Stewart WC. 24 hour intraocular pressure reduction with latanoprost compared to pilocarpine as third line therapy in exfoliation glaucoma. **Eye** 2001;15:59-62.
- (246) Stewart WC, Sharpe ED, Stewart JA, Holmes KT, Latham KE. Additive efficacy of unoprostone isopropyl 0.12% (Rescula) to latanoprost 0.005%. **Am J Ophthalmol** 2001;131:339-44.
- (247) CIBA symposium on Rescula. New Strategies in the management of Glaucoma. **Supplement Review of Ophthalmol** June 2001.
- (248) Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. **Am J Ophthalmol** 2001;131:631-5.
- (249) Stewart WC, Holmes KT, Johnson MA. Washout periods for brimonidine 0.2% and latanoprost 0.005%. **Am J Ophthalmol** 2001;131:798-99.
- (250) Stewart WC. Evaluating a New Glaucoma Drop. **Ophthalmol Management** 2001:14-7.
- (251) Stewart WC, Day DG, Holmes KT, Stewart JA. Effect of timolol 0.5% gel and solution on pulmonary function in older glaucoma patients. **J Glaucoma** 2001;10:227-32.
- (252) Konstas AGP, Stewart WC, Topouzis F, Tersis I, Holmes KT, Stangos NT. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. **Am J Ophthalmol** 2001;131:729-33.
- (253) Jackson AL, Stewart WC, Stewart JA, Holmes KT. Cardiovascular effects of timolol, brimonidine and brimonidine/timolol in combination. **Invest Ophthalmol Vis Sci** 2001;42:S418.
- (254) Konstas AGP, Holmes KT, Stewart WC. A comparison of the efficacy and safety of latanoprost 0.005% every evening versus timolol/dorzolamide fixed combination twice daily. **Invest Ophthalmol Vis Sci** 2001;42:S420.

ARTICLES (continued)

- (255) Stewart WC, Mundorf T, Haque R, Brown A, Kapik B, Shams N, Unoprostone Study Group. Comparison of the IOP-lowering efficacy and safety of the docosanoid unoprostone isopropyl 0.15% versus timolol maleate 0.5% dosed twice daily for 6 months in patients with primary open-angle glaucoma or ocular hypertension. **Invest Ophthalmol Vis Sci** 2001;42:S557
- (256) DuBiner H, Cooke D, Dirks M, Stewart WC, VanDenburgh AM, Felix C. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: A 30-day comparison with latanoprost. **Surv Ophthalmol** 2001;45:S353-360.
- (257) Stewart WC. Emerging therapies in the medical management of glaucoma. **Review Ophthalmol** 2001 June:9-23.
- (258) Stewart WC. Diurnal Curves Truly Measure Efficacy. **Review Ophthalmol** 2001 Nov;128-32.
- (259) Stewart WC. Maximizing medical therapy for glaucoma. **Review Ophthalmol** 2002 Feb;39-45.
- (260) Stewart WC. How the new prostaglandins stack up: A look at what clinical studies reveal about travoprost and bimatoprost in relation to latanoprost. **Review Ophthalmol** 2002 June.
- (261) Stewart WC, Halper LK, Johnson-Pratt L, Polis A, Hartenbaum D. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol. **J Ocul Pharmacol Ther** 2002;18:211-20.
- (262) Stewart WC. Reading between the lines: An interpretation of clinical studies. **J Ophthalmic Practice** 2002;20:81-2.
- (263) Stewart WC, Rhodes JS, Leech JN. Survey assesses red eye and prostaglandin use. **Review Ophthalmol** 2002 Apr:72-73.
- (264) Konstas AGP, Nakos E, Tersis I, Lallios NA, Leech JN, Stewart WC. A comparison of once daily morning versus evening dosing of concomitant latanoprost/timolol. **Am J Ophthalmol** 2002;133:753-757.
- (265) Small DS, Acheampong A, Reis B, Stern K, Stewart W, Berdy G, Epstein R, Foerster R, Forstot L, Tang-Liu DD. Blood concentrations of cyclosporine A during long-term treatment with cyclosporine A ophthalmic emulsions in patients with moderate to severe dry eye disease. **J Ocul Pharmacol Ther** 2002;18:411-418.
- (266) Stewart WC, Stewart JA, Crockete S, Kulilus C, Brown A, Shams N. Comparison of the cardiovascular effects of unoprostone 0.15%, timolol 0.5%, and placebo in healthy adults during exercise using a treadmill test. **Acta Ophthalmol Scand** 2002;80:272-276.
- (267) Stewart WC, Stewart JA, Jackson AL. Cardiovascular effects of timolol maleate, brimonidine or brimonidine/timolol maleate in concomitant therapy. **Acta Ophthalmol Scand** 2002;80:277-281.
- (268) Stewart WC, Leech J, Sharpe ED, Kulze J, Ellyn J, Day DG. An economic analysis of switching to latanoprost from a β -blocker or adding brimonidine or latanoprost to a β -blocker in open-angle glaucoma or ocular hypertension. **Am J Manag Care** 2002;8:S240-248.
- (269) Stewart WC, Sharpe ED, Stewart JA, Hott EC. The safety and efficacy of timolol 0.5% in xanthan gum versus timolol gel forming solution 0.5%. **Curr Eye Res** 2002;24:387-391.
- (270) Stewart WC. Know the structure know the medicine. **Review Ophthalmol** 2002 Sept;34-38.
- (271) Konstas AGP, Kozobolis VP, Tersis I, Leech J, Stewart WC. The efficacy and safety of the timolol/dorzolamide fixed combination versus latanoprost in exfoliation glaucoma. **Eye** 2003;17:41-46.

ARTICLES (continued)

- (272) Day DG, Schacknow PN, Wand M, Sharpe ED, Stewart JA, Leech J, Stewart WC. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. **Am J Ophthalmol** 2003;135:138-143.
- (273) Stewart WC, Kolker AE, Stewart JA, Leech JN, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. **Am J Ophthalmol** 2003;135:314-320.
- (274) Stewart WC, Stewart JA, Leech JN. Acute and chronic ocular symptomatology of dorzolamide 2% compared to placebo. **J Glaucoma** 2003;12:151-155.
- (275) Stewart WC, Stewart JA, Day DG, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. **Acta Ophthalmol Scand** 2003;81:242-246.
- (276) Stewart WC. European study assesses Xalacom. **Review Ophthalmol** 2003 Jun;75-77.
- (277) Konstas AGP, Papapanos P, Tersis I, Houliara D, Stewart WC. Twenty-four hour diurnal curve comparison of commercially available latanoprost 0.005% vs timolol/dorzolamide fixed combination. **Ophthalmology** 2003;110:1357-1360.
- (278) Kałużny JJ, Szaflik J, Czechowicz-Janicka K, Kałużny J, Orzalkiewicz A, Zaleska A, Krajewska, M, Stewart JA, Leech JN, Stewart WC. Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients. **Acta Ophthalmol Scand** 2003;81:349354.
- (279) Stewart WC, Stewart JA, Jenkins JN, Jackson AL. Corneal punctate staining with latanoprost, bimatoprost and travoprost. **J Glaucoma** 2003;12:475-479.
- (280) Stewart WC, ISV-205 Study Group. Prevention of corticosteroid induced intraocular pressure elevation from ISV-205. **Arch Ophthalmol** 2003;121:1543-1547.
- (281) Zimmerman TJ, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. **J Ocul Pharmacol Ther** 2003;19:405-415.
- (282) Stewart WC, Jackson AL, Jenkins JN. Can patients guess their intraocular pressure? **Am J Ophthalmol** 2004;137:350-351.
- (283) Konstas AGP, Hollo G, Astakhov YS, Teus MA, Akopov EL, Leech JN, Stewart WC. Factors associated with long-term progression or stability in exfoliation glaucoma. **Arch Ophthalmol** 2004;122:29-33.
- (284) Sharpe ED, Day DG, Beischel CJ, Rhodes, JS, Stewart JA, Stewart WC. Brimonidine purite 0.15% vs dorzolamide 2% each given twice daily to reduce the intraocular pressure in subjects with open-angle glaucoma or ocular hypertension. **Br J Ophthalmol** 2004;88:953-956.
- (285) Atkinson MJ, Stewart WC, Fain JM, Stewart JA, Dhawan R, Mozaffari E, Lohs J. A new measure of patient satisfaction with ocular hypotensive medications: The Treatment Satisfaction Survey - Intraocular Pressure (TSS-IOP). **Health Qual Life Outcomes** 2003;15:1:67.
- (286) Konstas AGP, Mylopoulos N, Karabatsas CH, Kozobolis VP, Diafas S, Papapanos P, Georgiadis N, Stewart WC. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. **Eye** 2004;18:893-899.

ARTICLES (continued)

- (287) Stewart WC, Day DG, Stewart JA, Holmes KT, Jenkins JN. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjects. **Eye** 2004;18:905-910.
- (288) Stewart WC. Review: Medical Management of Glaucoma by Tsai JC, Forbes M. **Am J Ophthalmol** 2004;137:218.
- (289) Stewart WC, Geiger AC, Jenkins JN. The benefit of repeated intraocular pressure measurements in clinical trials. **Arch Ophthalmol** 2004;122:936-937.
- (290) Stewart WC, Jackson AL, Jenkins JN. Dropout rates for intent-to-treat and per protocol analyses. **Am J Ophthalmol** 2004;137:639-645.
- (291) Stewart WC, Stewart JA, Day DG, Sharpe ED, Jenkins JN. Efficacy and safety of the latanoprost/timolol maleate fixed combination versus concomitant brimonidine and latanoprost therapy. **Eye** 2004;18:990-995.
- (292) Sharpe ED, Henry CJ, Mundorf TK, Day DG, Stewart JA, Jenkins JN, Stewart WC. Brimonidine 0.2% versus unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension. **Eye** 2005;19:35-40.
- (293) Konstas AGP, Kozobolis VP, Lalos N, Christodoulakis E, Stewart JA, Stewart WC. Daytime diurnal curve comparison between the fixed combinations of latanoprost/timolol and dorzolamide/timolol. **Eye** 2004;18:1264-1269.
- (294) Stewart WC, Stewart JA, Day DG, Leech J. The safety and efficacy of unoprostone 0.15% versus brimonidine 0.2%. **Acta Ophthalmol Scand** 2004;82:161-165.
- (295) Hamacher T, Schinzel M, Schölzel-Klatt A, Neff H-M, Maier H, Schlaffer G, Beausencourt E, Jütte M, Scholz R, Lorgner C, Stewart WC. Short-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from mono- and adjunctive therapies. **Br J Ophthalmol** 2004;88:1295-1298.
- (296) Day DG, Schacknow PN, Sharpe ED, Ellyn JC, Kulze JC, Threlkeld AB, Jones ED, Brown RH, Jenkins JN, Stewart WC. A persistency and economic analysis of latanoprost, bimatoprost or beta-blockers in patients with open-angle glaucoma or ocular hypertension. **J Ocul Pharmacol Ther** 2004;20:383-392.
- (297) Konstas AGP, Bányai L, Blask K-D, Váth J, Kozobolis VP, Trüb PR, Tsironi S, Maloutas S, Teus MA, Stewart WC. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. **J Ocul Pharmacol Ther** 2004;20:375-382.
- (298) Stewart WC, Konstas AGP. Ocular and systemic side effects of latanoprost. Reply to J Kountouras et al. **Eye** 2005;19:805-806.
- (299) Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. **Eur J Ophthalmol** 2004;14:407-415.
- (300) Stewart WC. Prevention of steroid-induced intraocular pressure elevation-reply. **Arch Ophthalmol** 2005;123:1020.
- (301) Stewart WC. Preventing steroid-induced glaucoma-reply. **Arch Ophthalmol** 2005;123:1018.
- (302) Stewart WC, Konstas AGP, Pfeiffer N. Patient and ophthalmologist attitudes concerning compliance and dosing in glaucoma treatment. **J Ocul Pharmacol Ther** 2004;20:461-469.

ARTICLES (continued)

- (303) Bayer A, Weiler W, Oeverhaus U, Skrotzki F-E, Stewart WC, Xplore Observation Group. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. **J Ocul Pharmacol Ther** 2004;20:470-478.
- (304) Stewart WC, Jenkins JN, Johnson M. Treatment patterns for ocular hypertension. **Review Ophthalmol** 2004 Oct;111-117.
- (305) Konstas AGP, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. **Ophthalmology** 2005;112:262-266.
- (306) Konstas AGP, Boboridis K, Tzetzis D, Kallinderis K, Jenkins JN, Stewart WC. 24-hour intraocular pressure short-term control with the latanoprost/timolol maleate fixed combination versus latanoprost, both dosed once each evening, in primary open-angle glaucoma patients. **Arch Ophthalmol** 2005;123:898-902.
- (307) Konstas AGP, Karabatsas CH, Lallos N, Georgiadis N, Kotsimpou A, Stewart JA, Stewart WC. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects. **Ophthalmology** 2005;112:603-608.
- (308) Day DG, Sharpe ED, Beischel CJ, Jenkins JN, Stewart JA, Stewart WC. Safety and efficacy of bimatoprost 0.03% versus timolol maleate 0.5%/dorzolamide 2% fixed combination. **Eur J Ophthalmol** 2005;15:336-342.
- (309) Stewart WC, Jenkins JN, Stewart JA. Corneal thickness after refractive surgery. **Ophthalmology** 2005;112:1637.
- (310) Day DG, Sharpe ED, Atkinson MJ, Stewart JA, Stewart WC. The Clinical Validity of the Treatment Satisfaction Survey for Intraocular Pressure in Ocular Hypertensive and Glaucoma Patients. **Eye** 2006;20:583-590.
- (311) Konstas AGP, Hollo G, Astakhov YS, Teus MA, Akopov EL, Jenkins JN, Stewart WC. Presentation and longterm follow-up of exfoliation glaucoma in Greece, Spain, Russia and Hungary. **Eur J Ophthalmol** 2006;16:60-66.
- (312) Stewart WC. Combination therapy: Is the whole greater? **Review Ophthalmol** 2005 Jun:60-62.
- (313) Stewart WC, Jackson AL, Emkin A. Physician attitudes towards new AMD treatments. **Review Ophthalmol** 2005 Aug;58-60.
- (314) Stewart WC, Jenkins JN, Stewart JA. Survey assesses prostaglandin use: A snap shot of how physicians are using two of the predominant glaucoma medications in their clinics. **Review Ophthalmol** 2005 Oct; 123-124.
- (315) Stewart WC, Heier JS, Tolentino MJ. Macugen treatment: Making it work for you. **Review Ophthalmol** 2005 Sept;75-77.
- (316) Fiscella R, Stewart WC. Letter to the editor: Patient persistency with glaucoma therapy. **J Ocul Pharmacol Ther** 2005;21:349-350.
- (317) Stewart WC, Passmore CL. Pharma & ophthalmology: A cautious dance. An unusual ophthalmology-specific survey assesses how the profession views its relations with pharmaceutical companies. **Review Ophthalmol** 2005 Oct;51-53.
- (318) Stewart WC, Day DG, Jenkins JN, Passmore CL, Stewart JA. Mean intraocular pressure and progression based on corneal thickness in primary open-angle glaucoma. **J Ocul Pharmacol Ther** 2006;22:26-33.

ARTICLES (continued)

- (319) Konstas AGP, Mikropoulos D, Kaltsos K, Jenkins JN, Stewart WC. 24-hour intraocular pressure control obtained with evening versus morning dosed travoprost in primary open-angle glaucoma. **Ophthalmology** 2006;113:446-450.
- (320) Konstas AGP, Lake S, Economou AI, Kaltsos K, Jenkins JN, Stewart WC. 24-hour control with latanoprost/timolol maleate fixed combination versus timolol maleate. **Arch Ophthalmol** 2006;124:1553-1557.
- (321) Konstas AGP, Topouzis F, Leliopoulou O, Pappas T, Georgiadis N, Jenkins JN, Stewart WC. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. **Ophthalmology** 2006;113:761-765.
- (322) Nasser QJ, Stewart WC. Glaucoma treatment and diagnostic trends. **Review Ophthalmol** 2006 Mar.
- (323) Konstas AGP, Kozobolis VP, Katsimpris IE, Boboridis K, Koukoula S, Jenkins JN, Stewart WC. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. **Ophthalmology** 2007;114:653-657.
- (324) Holló G, Chiselita D, Petkova N, Cvenkel B, Liehneova I, Izgi B, Berta A, Szaflik J, Turacli E, Stewart WC. The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. **Eur J Ophthalmol** 2006;16:816-823.
- (325) Harasymowycz P, Hutnik CML, Nicoleta M, Stewart WC. The efficacy and safety of latanoprost 0.005% versus timolol maleate 0.5% gel forming solution each given once every evening in primary open-angle glaucoma or ocular hypertension. **Can J Ophthalmol** 2007;42:75-81.
- (326) Greven CM, Wells JA, Stewart WC. Neovascular age-related macular degeneration and chronic VEGF inhibition: Where do we go from here? **Review Ophthalmol** 2007 Feb;14.
- (327) Diafas S, Day DG, Stewart JA, Stewart WC. The use of dorzolamide versus other hypotensive agents to prevent glaucomatous progression. **Ther Clin Risk Manag** 2007;3:725-732.
- (328) Thelen U, Christ T, Schnober D, Hofstetter H-J, Stewart WC. Mid-term response with latanoprost therapy in German ocular hypertension patients. **Curr Eye Res** 2007;32:51-56.
- (329) Thelen U, Weiler W, Kirchhoff E, Fuchs H-B, Stewart WC. Clinical experience in the treatment of normal tension glaucoma with latanoprost in Germany. **J Ocul Pharmacol Ther** 2007;23:311-313.
- (330) Konstas AGP, Kozobolis VP, Tsironi S, Makridaki I, Efremova R, Stewart WC. Comparison of the 24-hour intraocular pressure lowering effect of latanoprost and dorzolamide/timolol fixed combination after 2 and 6 months of treatment. **Ophthalmology** 2008;115:99-103.
- (331) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Cost-effectiveness of treating ocular hypertension. **Ophthalmology** 2008;115:94-98.
- (332) Krufft B, Nelson LA, Stewart JA, Stewart WC. Adverse event reporting in ophthalmic clinical trials. **Ophthalmology** 2007;114:1420.
- (333) Stewart WC, Feldman R, Mychaskiw MA. Ocular blood flow in glaucoma: The need for further clinical evidence and patient outcomes research. **Br J Ophthalmol** 2007;91:1263-1264.

ARTICLES (continued)

- (334) Konstas AGP, Katsimpris IE, Kaltsos K, Georgiadou I, Kordelou A, Nelson LA, Stewart WC. 24-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. **Eye** 2008;22:1391-1397.
- (335) Stewart WC, Jenkins JN. Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies. **Eye** 2008;22:985-988.
- (336) Stewart WC, Stewart JA, Mychaskiw M. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. **Eye** 2009;23:132-140.
- (337) Konstas AGP, Irkec MT, Teus MA, Cvenkel B, Astakhov YS, Sharpe ED, Hollo G, Mylopoulos N, Bozkurt B, Pizzamiglio C, Potyomkin VV, Alemu AM, Nasser QJ, Stewart JA, Stewart WC. Mean intraocular pressure and progression based on corneal thickness in patients with ocular hypertension. **Eye** 2009;23:73-78.
- (338) Sonty S, Henry JC, Sharpe ED, Weiss MJ, Stewart JA, Nelson LA, Stewart WC. Success of switching to the dorzolamide/timolol fixed combination in patients who are insufficiently controlled by latanoprost monotherapy and who are timolol responders. **Acta Ophthalmol Scan** 2008;86:419-423.
- (339) Stewart WC, Konstas AGP, Nelson LA, Krufft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. **Ophthalmology** 2008;115:1117-1122.
- (340) Mulaney J, Sonty S, Ahmad A, Stewart JA, Stewart WC. Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost. **Eur J Ophthalmol** 2008;18:556-562.
- (341) Sharpe ED, Reynolds AC, Skuta GL, Jenkins JN, Stewart WC. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. **Curr Eye Res** 2007;32:1037-1043.
- (342) Stewart WC, Stewart JA, Nelson LA, Krufft B. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. **Eur J Ophthalmol** 2008;18:199-204.
- (343) Stewart WC, Stewart JA, Nelson LA, Krufft B. Mean standard deviations for common glaucoma treatments. **Acta Ophthalmol Scan** 2009;87:112-4.
- (344) Konstas AG, Tsironi S, Vakalis AN, Nasr MB, Stewart JA, Nelson LA, Stewart WC. Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open-angle and exfoliative glaucoma. **Acta Ophthalmol Scan** 2009;87:71-76.
- (345) Stewart WC, Feldman R, Mychaskiw MA. Reply to letter to editor regarding: Ocular blood flow in glaucoma: The need for further clinical evidence and patient outcomes research. **Br J Ophthalmol** 2008;92:1301-1302.
- (346) Cvenkel B, Stewart JA, Nelson LA, Stewart WC. Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. **Curr Eye Res** 2008;33:163-168.
- (347) Sharpe ED, Williams RD, Stewart JA, Nelson LA, Stewart WC. A comparison of dorzolamide/timolol fixed combination versus bimatoprost in patients with open-angle glaucoma who are insufficiently controlled on latanoprost. **J Ocul Pharmacol Ther** 2008;24:408-413.
- (348) Kałużny J, Sobiecki R, Czechowicz-Janicka K, Kecik D, J. Kałużny BJ, Stewart JA, Stewart WC. Efficacy and safety of latanoprost versus the pilocarpine/timolol maleate fixed combination in patients with primary open-angle glaucoma or ocular hypertension. **Acta Ophthalmol Scan** 2008;86:860-5.

ARTICLES (continued)

- (349) Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AGP, Stewart WC. 24-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. **Br J Ophthalmol** 2008;92:1227-1231.
- (350) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Reply to Letter to the Editor, Brown GC & Brown MM, entitled, "Cost-effectiveness". **Ophthalmology** 2008;115:1433-1434.
- (351) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Reply to Letter to the Editor, Litcher PR, entitled, "Cost-effectiveness". **Ophthalmology** 2008;115:1853.
- (352) Stewart WC, Kolker AE, Sharpe ED, Day DG, Konstas AG, Hollo G, Astakhov YS, Teus MA, Stewart JA. Long-term progression at individual mean intraocular pressure levels in primary open-angle and exfoliative glaucoma. **Eur J Ophthalmol** 2008;18:765-770.
- (353) Feldman RM, Stewart RH, Stewart WC, Jia G, Smugar SS, Galet VA. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma. **Curr Med Res Opin** 2008;24:2403-2412.
- (354) Konstas AGP, Mikropoulos D, Dimopoulos AT, Moumtzis G, Nelson LA, Stewart WC. Second-line therapy with dorzolamide/timolol or latanoprost/timolol fixed combination versus adding dorzolamide/timolol fixed combination to latanoprost monotherapy. **Br J Ophthalmol** 2008;92:1498-1502.
- (355) Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. **Clin Ophthalmol** 2008;2:613-621.
- (356) Stewart WC, Stewart JA, Nasser QN, Mychaskiw MA. Glaucoma Dialogue discussing Cost-effectiveness of treating ocular hypertension. **Ophthalmology** 2008;115:94-98. **International Glaucoma Review** 2008; 10:6-9.
- (357) Alemu AM, Nelson LA, Kruff B, Stewart JA, Stewart WC. Epidemiology of glaucoma in central Ethiopia. **Int J Ophthalmol** 2008;8:1729-1733.
- (358) Stewart WC. Reply to Letter to the Editor, Tuulonen A & Azuara-Blanco A, entitled, "Cost-effectiveness". **Ophthalmology** 2009;116:167.
- (359) Stewart WC. Book review of Curbside Consultation in Glaucoma. **Am J Ophthalmol** 2009 Jan;147:187.
- (360) Tabet R, Stewart WC, Feldman R, Konstas AGP. A Review of Additivity to Prostaglandin Analogs: Fixed and Unfixed Combinations. **Surv Ophthalmol** 2008;53:S85-S92.
- (361) Godfrey DA, Peplinski LS, Stewart JA, Stewart WC. A comfort comparison of travoprost BAK free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension. **Clin Ophthalmol** 2009;3:189-194.
- (362) Konstas AG, Mikropoulos D, Haidich AB, Ntampos K, Stewart WC. 24-hour intraocular pressure control with the travoprost/timolol fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma. **Br J Ophthalmol** 2008;93:481-5.
- (363) Sharmini AT, Yin N, Lee SS, Jackson AL, Stewart WC. Mean target intraocular pressure and progression rates in chronic angle-closure glaucoma. **J Ocul Pharmacol Ther** 2009;25:71-6.
- (364) Seong GJ, Rho SH, Kim CS, Moon JI, Kook MS, Kim YY, Ma KT, Hong YJ, Nelson LA, Kruff B, Stewart JA, Stewart WC. Potential benefit of intraocular pressure reduction in normal-tension glaucoma in South Korea. **J Ocul Pharmacol Ther** 2009;25:91-6.

ARTICLES (continued)

- (365) Konstas AGB, Pikilidou MI, Tsironi S, Mikropoulos D, Kozobolis VP, Sarafidis PA, Lasaridis AN, Nelson LA, Stewart WC. 24-hour intraocular pressure and blood pressure levels with latanoprost/timolol fixed combination versus timolol. **Current Eye Research** 2009;34:369-377.
- (366) Olander KW, Galet VA, Jia G, Smugar SS, Stewart WC. Relationship between visual field severity and response to fixed combination dorzolamide/timolol or timolol alone. **J Ocul Pharmacol Ther** 2009;25:357-364.
- (367) Stewart WC, Krufft B, Nelson LA, Stewart JA. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. **Eur J Ophthalmol** 2009;19:588-593.
- (368) Stewart WC, Konstas AGP. Reply to Letter to Editor, Mehdizadeh, Tehrani & Nowroozzadeh, entitled "Corneal Thickness and Glaucoma Medications". **Ophthalmology** 2009 Jul;116:1417.
- (369) Stewart WC, Konstas AGP. Reply to Letter to Editor, Rao & Sekhar, entitled, "Relative Efficacy of Prostaglandins". **Ophthalmology** 2009 Jul;116:1418.
- (370) Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost, travoprost and bimatoprost for the treatment of glaucoma in Norway, Sweden and Denmark, using a decision-analytic health Economic model. **Int J Ophthalmology** 2009;9:812-816.
- (371) Stewart WC, Pfeiffer N, Mathis HM. Meta-analysis of articles evaluating routine intraocular pressure control for monotherapy in the United States and Germany. **Eur J Ophthalmol** 2009;19:769-775.
- (372) Sonty S, Mundorf TK, Stewart JA, Stewart WC. Short-Term Tolerability of Once-Daily Timolol Hemihydrate 0.5%, Timolol Maleate in Sorbate 0.5%, and Generic Timolol Maleate Gel-Forming Solution 0.5% in Glaucoma and/or Ocular Hypertension: A Prospective, Randomized, Double-Masked, Active-Controlled, Three-Period Crossover Pilot Study. **Clin Ther** 2009;31:2063-2071.
- (373) Stewart WC, Stewart JA, Demos CM, Turner M. Serious adverse event reporting. **Ophthalmology** 2009;16:2485.
- (374) Stewart WC, Kristoffersen CJ, Demos CM, Fsadni MG, Stewart JA. Incidence of conjunctiva exposure following drainage device implantation in patients with glaucoma. **Eur J Ophthalmol** 2010;20:124-30.
- (375) Stewart WC, Stewart JA, Mychaskiw M. Response to Anderson et al. **Eye** 2009;23:2264.
- (376) Stewart WC, Robin AL, Sharpe ED, Hennessy A, Stewart JA. The motivation to perform glaucoma clinical trials. **Ophthalmology** 2010;117:397.
- (377) Stewart WC, Konstas AGP, Krufft B, Mathis HM, Stewart JA. Meta-analysis of 24-hour intraocular pressure fluctuation studies and the efficacy of glaucoma medicines. **J Ocul Pharmacol Ther** 2010;26:175-80.
- (378) Alemu AM, Kristoffersen CJ, Kristoffersen MS, Stewart JA, Stewart WC. Long-term benefit of reduced intraocular pressure in primary open-angle glaucoma patients in Ethiopia. **Eur J Ophthalmol** 2010;20:310-5.
- (379) Pfeiffer N, Scherzer M-L, Maier H, Schoelzel S, Jasek MC, Stewart JA, Stewart WC. Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. **Clin Ophthalmol** 2010;4:459-66.
- (380) Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in glaucoma patients using topical intraocular pressure-lowering medications. **Cornea** 2010;29:618-21.

ARTICLES (continued)

- (381) Stewart WC, Demos CM, Turner MK, Stewart JA. Risk factors for subject withdrawals in clinical trials evaluating glaucoma medications. **Graefes Arch Clin Exp Ophthalmol** 2010;248:1007-12.
- (382) Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. **Arch Ophthalmol** 2010;128:825-33.
- (383) Quaranta L, Konstas AGP, Rossetti L, Garcia-Feijoo J, O'Brien C, Nasr MB, Fogagnolo P, Demos CM, Stewart JA, Stewart WC. Untreated 24-hour intraocular pressures measured with Goldmann applanation tonometry versus nighttime supine pressures with Perkins applanation tonometry. **Eye** 2010;24:1252-8.
- (384) Holló G, Cvenkel B, Teus MA, Irkec MT, Astakhov YS, Chiselita D, Petkova N, Liehneová I, Kaluzny BJ, Kóthy P, Bozkurt B, Akopov EL, Stewart JA, Kristoffersen MS, Kristoffersen CJ, Stewart WC. Is there any difference in target intraocular pressure for exfoliative glaucoma patients with cardiovascular disease history? **Eur J Ophthalmol** 2010;20:1000-6.
- (385) Lee PW, Doyle A, Stewart JA, Kristoffersen CJ, Stewart WC. Meta-analysis of timolol on the diurnal and nighttime intraocular pressure and blood pressure. **Eur J Ophthalmol** 2010;20:1035-41.
- (386) Stewart WC, Sharpe ED, Kristoffersen CJ, Nelson LA, Stewart JA. Association of strength of religious adherence to attitudes regarding glaucoma or ocular hypertension. **Ophthalmic Res** 2011;45:53-6.
- (387) Stewart WC, Demos CM, Turner M, Stewart JA. Factors associated with site requirement for glaucoma clinical trials. **Graefes Arch Clin Exp Ophthalmol** 2010;248:1527-8.
- (388) Stewart WC, Konstas AG, Quaranta L, Rossetti L, Garcia-Feijoo J, O'Brien C, Nasr MB, Fogagnolo P, Demos CM, Stewart JA. Reply to Letter to the Editor, Weinreb RN, Liu JHK, Medeiros FN, entitled "24-h intraocular pressures measured with two tonometers". **Eye** 2010;24:1531-2.
- (389) Konstas AG, Mikropoulos DG, Embeslidis TA, Dimopoulos AT, Papanastasiou A, Haidich A-B, Stewart WC. 24-hour intraocular pressure control with evening dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma. **Eye** 2010;24:1606-13.
- (390) Stewart WC, Crean CS, Zink RC, Brubaker K, Haque RM, Hwang DG. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. **Am J Ophthalmol** 2010;150:744-51.
- (391) Miyashiro MJ, Lo SC, Stewart JA, Stewart WC. Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients. **Clin Ophthalmol** 2010;4:1355-9.
- (392) Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. **Curr Eye Res** 2011;36:391-398.
- (393) Stewart WC, Adams MP, Stewart JA, Nelson LA. Survey of practice-related stress among United States and European ophthalmologists. **Graefes Arch Clin Exp Ophthalmol** 2011;249:1277-80.
- (394) Stewart WC, Magrath GN III, Demos CM, Nelson LA, Stewart JA. Predictive value of the efficacy of glaucoma medications in animal models: Pre-clinical to regulatory studies. **Br J Ophthalmol** 2011;95:1355-1360.

ARTICLES (continued)

- (395) Holló G, Thelen U, Teus MA, Quaranta L, Ferkova S, Babić N, Misiuk-Hojlo M, Mikropoulos DG, Kaluzny BJ, Kozobolis V, Januleviciene I, Kóthy P, Camara C, Russo A, Krzyzanowska-Berkowska P, Cieślińska I, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Long-term outcomes of prostaglandin analog vs. timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. **J Ocul Pharmacol Ther** 2011;27:493-8.
- (396) Ma KT, Kim CY, Seong GJ, Lee SH, Park JW, Ha SJ, Cho BJ, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Intraocular pressure reduction in normal-tension glaucoma patients in South Korea. **Int Ophthalmol** 2011;31:355-361.
- (397) Holló G, Quaranta L, Cvenkel B, Astakhov YS, Teus MA, Kóthy P, Miglior S, Riva I, Akopov EL, Gros J, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Risk factors associated with progression in exfoliative glaucoma patients. **Ophthalmic Res** 2011;47:208-213.
- (398) Goldberg I, Crowston JG, Jasek MC, Stewart JA, Stewart WC. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. **J Glaucoma** 2012;21:55-59.
- (399) Konstas AG, Quaranta L, Mikropoulos DG, Nasr MB, Russo A, Jaffee HA, Stewart JA, Stewart WC. Peak intraocular pressure and glaucomatous progression in primary open-angle glaucoma. **J Ocul Pharmacol Ther** 2012;28:26-32.
- (400) DeMill DL, Wirostko BM, Nelson LA, Stewart JA, Stewart WC. Average eye versus highest intraocular pressure analyses in glaucoma clinical trials. **Ophthalmic Res** 2013;49:49-51.
- (401) Sharpe RA, Nelson LA, Stewart JA, Stewart WC. Intraocular pressure efficacy of glaucoma medications versus placebo in Phase II compared to later phase trials. **Br J Ophthalmol** 2013;97:121-125.
- (402) Stewart WC, Adams MP, Stewart JA, Nelson LA. Review of clinical medicine and religious practice. **J Relig Health** 2013;52:91-106.
- (403) Stewart WC, Stewart JA, Krufft B, Nelson LA. Challenges facing ophthalmic startup companies in developing new devices or medicines. **Acta Ophthalmol** 2013;91:e81-83.
- (404) Stewart WC, Stewart JA, Nelson LA. The start-up: From dream to reality. **Review Ophthalmol** 2013 Apr; 62-71.
- (405) Thelen U, Schnober D, Schölzel S, Kristoffersen MS, Nelson LA, Stewart JA, Stewart WC. Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany. **Int J Ophthalmol**. 2013;6:155-159.
- (406) Stewart WC, Oehler JC, Choplin NT, Markoff JI, Moster MR, Ichhpujani P, Nelson LA. A comfort survey of timolol hemihydrate 0.5% solution once or twice daily vs. timolol maleate in sorbate. **Journal of Current Glaucoma Practice**, Jan-Apr 2013;7:11-16.
- (407) Stewart WC, DeMill DL, Wirostko BW, Nelson LA, Stewart JA. A review of pigment dispersion and exfoliation glaucoma diagnosis on intraocular pressure in clinical trials evaluating primary open-angle glaucoma and ocular hypertension. **J Glaucoma** 2013;22:506-509.
- (408) Dehning DO, Nelson LA, Stewart JA, Stewart WC. Does religious adherence help diabetic patients' well-being? **J Christian Nurs** 2013;30:e1-11.

ARTICLES (continued)

- (409) Stewart WC, Chaney PG, Stewart JA, Krufft B, Nelson LA. Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. **Acta Ophthalmol** 2013; 91:496-497.
- (410) Stewart WC, Limtong AC, Magrath GN, Rembold JC, Nelson LA, Stewart JA. Lower limits of intraocular pressure in glaucoma clinical trials. **J Glaucoma** 2014;23:e105-107.
- (411) Stewart WC, Stewart JA, Nelson LA. Doing it right: First steps in creating a pharma start-up. **Review Ophthalmol** 2014 Apr;54-62.
- (412) Stewart WC, Stewart JA, Nelson LA. Glaucoma clinical trial design: a review of the literature. **Perspect Clin Res** 2014;5:108-114.
- (413) Sharpe RA, Nelson LA, Stewart JA, Stewart WC. The placebo effect in early phase glaucoma clinical trials. **Curr Eye Res** 2015;40:653-6.
- (414) Goertz AD, Stewart WC, Burns WR, Stewart JA, Nelson LA. Review of the impact of presbyopia on quality of life in the developing and developed world. **Acta Ophthalmologica** 2014;92:497-500.
- (415) DeMill DL, Wirostko BM, Nelson LA, Stewart WC. Upper limits of intraocular pressure in glaucoma clinical trials. **Clin Experiment Ophthalmol** 2015:43:84-5.
- (416) Stewart WC, Stewart JA, Nelson LA. How to assess an ophthalmic start-up. **Review Ophthalmol** 2015 Apr;62-69.
- (417) Sharpe RA, Davidson J, Nelson LA, Stewart JA, Stewart WC. Techniques to reduce the placebo effect in glaucoma clinical trials. **Ophthalmic Res** 2015;54:3-5.
- (418) Sharpe RA, Austin JP, Krufft B, Nelson LA, Stewart JA, Stewart WC. Description of ophthalmic pharmaceutical and device start-up companies. **Ophthalmic Res** 2015;54:6-9.
- (419) Stewart WC, Nelson LA, Eveleth DD. Endothelial Regeneration: Help Is on the Way. **Review Ophthalmol** 2015 Nov;74-80.
- (420) DeMill DL, Wirostko B, Stewart JA, Nelson LA, Stewart WC. Single- versus double-masking in glaucoma clinical trials. **Perspect Clin Res** 2016;7:147-148.

IN PRESS:

Stewart WC, Nelson LA, Krufft B, Stewart JA. Ophthalmic start-up CEO's perceptions of development hurdles. *Ophthalmic Res* 2017; in press.

Stewart WC, Krufft B, Nelson LA, Stewart JA. Progress of Ophthalmic Pharmaceutical Start-up Companies. *Acta Ophthalmol* 2017; in press.

Stewart WC, Nelson LA, Stewart JA. What Data Sources Do Ophthalmologists Trust? *Evid Based Med*. 2017; in press.

WILLIAM C. STEWART, MD

INVITED LECTURES

- (1) Presentation, An Overview of Glaucoma, *Regional Representative Update, Duke University, Durham, NC, November 1986.*
- (2) Presentation, An Overview of Visual Field Diagnosis, *Ophthalmic Technician Course, Duke University, Durham, NC, March 1987.*
- (3) Presentation, An Overview of Glaucoma, *Ophthalmic Technician Course, Duke University, Durham, NC, March 1987.*
- (4) Participant, Glaucoma Round-Table, *South Carolina-North Carolina State Society Meeting, October 1987.*
- (5) Presentation, Clinical Optic Disc Diagnosis, *Medical University of South Carolina Annual Meeting, Charleston, SC, May 1988.*
- (6) Lab Instructor, Special Focus Anterior Segment Laser Course, *American Academy of Ophthalmology, June 1989.*
- (7) Participant, Fistulizing Techniques in Laser Surgery, *Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.*
- (8) Participant, Anterior Segment Laser Surgery, *Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.*
- (9) Presentation, Reopening a Fistula, Creating a Fistula, and Closing a Cyclodialysis Cleft, *Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.*
- (10) Presentation, Pupilloplasty, Peripheral Iridoplasty, Iris Sphincterotomy, Photomydriasis, and Goniophotocoagulation, *Special Focus Anterior Segment Laser Course, American Academy of Ophthalmology, June 1989.*
- (11) Presentation, Medical Management of Glaucoma, *Regional Representative Update, Charleston SC, June 1989.*
- (12) Presentation, Beta Adrenergic Blockers, *Regional Representative Update, Charleston SC, January 1990.*
- (13) Presentation, Management of the Postoperative Trabeculectomy Patient, *Grand Rounds, Medical University of South Carolina, Charleston, SC, February 1990.*
- (14) Presentation, Glaucoma Pharmacology Update, *Grand Rounds, Medical University of South Carolina, Charleston, SC, February 1990.*
- (15) Presentation, Review of Cyclodestructive Procedures, *Charleston Ophthalmology Society Meeting, Charleston, SC, April 1990.*
- (16) Presentation, Neovascular Glaucoma, *Retina Update Meeting, Medical University of South Carolina, Charleston, SC, May 1990.*
- (17) Presentation, Treatment of Glaucoma, *Regional Representative Update, Charleston SC, August 1990.*
- (18) Presentation, Ocular Eye Injuries, *Medical Society of Dillon, Dillon, South Carolina, August 1990.*

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (19) Presentation, The Secondary Glaucomas, *American Academy of Ophthalmology*, October 1990.
- (20) Presentation, Treatment of Glaucoma, Regional Meeting, Charleston, SC, December 1990.
- (21) Presentation, The Secondary Glaucomas, *American Academy of Ophthalmology*, October 1991.
- (22) Moderator, Saturday Session, *American Glaucoma Society*, San Diego, CA, 1991.
- (23) Presentation, Glaucoma Laser Review and Update, *Grand Rounds, Medical University of South Carolina*, Charleston, SC, February 29, 1992.
- (24) Presentation, Low-tension glaucoma, *Grand Rounds, Medical University of South Carolina*, Charleston, SC, February 29, 1992.
- (25) Presentation, Surgical Approach to Glaucoma and Cataract, *Medical University of South Carolina, Department of Ophthalmology, Annual Meeting*, Charleston, SC, May 22, 1992.
- (26) Presentation, Clinical Evaluation and Management of Low Tension Glaucoma, *American Academy of Ophthalmology*, November 1992.
- (27) Presentation, Current and Future Use of Glaucoma Medications, *American Academy of Ophthalmology*, November 1992.
- (28) Presentation, Refractory Glaucoma in Children, *Medical University of South Carolina, Department of Ophthalmology, Annual Meeting*, Kiawah, SC, June 13, 1993.
- (29) Moderator, Wednesday Session (Mechanisms of Glaucoma and Clinical Observations), *American and European Glaucoma Societies Meeting*, Iceland, July 7, 1993.
- (30) Presentation, Clinical Evaluation and Management of Low Tension Glaucoma, *American Academy of Ophthalmology*, November 1993.
- (31) Presentation, Current and Future Use of Glaucoma Medications, *American Academy of Ophthalmology*, November 1993.
- (32) Presentation, Medical Treatment of Glaucoma, *Kansas City Society of Ophthalmology and Otolaryngology*, Annual Clinical Conference, December 9-10, 1993.
- (33) Presentation, Visual Field Interpretation, *Kansas City Society of Ophthalmology and Otolaryngology*, Annual Clinical Conference, December 9-10, 1993.
- (34) Presentation, Dealing with Glaucoma Suspects, *Kansas City Society of Ophthalmology and Otolaryngology*, Annual Clinical Conference, December 9-10, 1993.
- (35) Moderator, Cartelol Advisory Board Meeting, Rancho Mirage, CA, February 26, 1994.
- (36) Presentation, Current and Future Use of Glaucoma Medications, *Scandinavian Symposium*, Stockholm, Sweden, April 24, 1994.
- (37) Presentation, Diagnosis and Management of Early Glaucoma, *27th Panhellenic Ophthalmological Congress*, May 27, 1994.
- (38) Presentation, Medical Therapy of Glaucoma, *27th Panhellenic Ophthalmological Congress*, May 27, 1994.
- (39) Participation, Round-table Treatment Problems in Glaucoma, *27th Panhellenic Ophthalmological Congress*, May 27, 1994.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (40) Participation, Round-table Diagnostic Problems in Glaucoma, *27th Panhellenic Ophthalmological Congress*, May 28, 1994.
- (41) Presentation, Future of Glaucoma Research, Basel, Switzerland, May 31, 1994.
- (42) Presentation, Low-Tension Glaucoma, *Richland County Ophthalmology Society*, July 26, 1994.
- (43) Discussant, Johnstone MA: Incidence of Endophthalmitis After Mitomycin Filtering Surgery in 508 Eyes, *American Academy of Ophthalmology*, November 2, 1994.
- (44) Presentation, Serum Lipid Levels and the Ophthalmologist, *Parker Health Lecture, American Academy of Ophthalmology*, October 31, 1994.
- (45) Moderator, Changing Perspectives in the Clinician's Viewpoint, *OAPI advisory board meeting*, Florida Keys, January 14, 1995.
- (46) Presentation, New and Current Glaucoma Medications, Cincinnati, Ohio, March 29, 1995.
- (47) Presentation, Medical Treatment of Glaucoma, Louisville, Kentucky, June 13, 1995.
- (48) Presentation, Prostaglandin Update, *Prostaglandin Symposium, Society of Ophthalmologists of Europe*, Milan, Italy, June 27, 1995.
- (49) Presentation, Prostaglandin Update, *Prostaglandin Symposium, Society of Ophthalmologists of Europe*, Milan, Italy, June 28, 1995.
- (50) Presentation, Glaucoma Update, *Grand Rounds*, Kansas City, Missouri, August 24, 1995.
- (51) Chairman, Neuroprotection Session, *International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceuticals*, Geneva, Switzerland, September 30, 1995.
- (52) Presentation, Future of Glaucoma Therapy, Zürich, Switzerland, October 2, 1995.
- (53) Presentation, Overview of Diagnosis and Treatment of Glaucoma, *Training Session*, Charleston, SC, October 10, 1995.
- (54) Participant, Future of Glaucoma Therapy, *Round-Table*, Rockville, MD, October 14, 1995.
- (55) Presentation, Clinical Evaluation and Management of Low-Tension Glaucoma, *American Academy of Ophthalmology*, Atlanta, GA, October 30, 1995.
- (56) Presentation, Apraclonidine, Glaucoma Diagnostic and Therapeutic Progress Scientific Session (in combination with Prevent Blindness America meeting), *American Academy of Ophthalmology*, Atlanta, GA, November 1, 1995.
- (57) Presentation, Current and Future Use of Glaucoma Medications, *American Academy of Ophthalmology*, Atlanta, GA, November 2, 1995.
- (58) Presentation, Review and Management of Glaucoma, *South Carolina Satellite Symposium*, December 12, 1995.
- (59) Presentation, Betimol Research Potential, *Research & Development and Marketing*, Atlanta, GA, January 1996.
- (60) Presentation, Results of Blood Pressure in Carteolol vs. Timolol Maleate Study, *OAPI advisory meeting*, Palm Springs, CA, February 17, 1996.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (61) Chairman and Panel Discussion Leader, Betimol, *Advisory Board Session*, Miami, FL, February 1996.
- (62) Presentation, New and Future Medicines, Atlanta, GA, April 1996.
- (63) Presentation, Xalatan Update, *PIOP annual meeting*, Dallas, TX, April 29, 1996.
- (64) Presentation, Betimol Overview, *California Drug Regulatory Agency*, June, 1996.
- (65) Presentation, New and Future Medicines, *National Ophthalmics Speakers Program*, Ottawa, Canada, June 21, 1996.
- (66) Presentation, New Therapies in Glaucoma, Capetown, South Africa, July 4-7, 1996.
- (67) Moderator, Surgery Session, Capetown, South Africa, July 4-7, 1996.
- (68) Participant, Panel Discussion, Capetown, South Africa, July 4-7, 1996.
- (69) Presentation, Treatment of Glaucoma, *Training Seminar*, Kalamazoo, Michigan, July 11, 1996.
- (70) Presentation, Xalatan Overview, *Training Seminar*, Kalamazoo, Michigan, July 11, 1996.
- (71) Presentation, Xalatan Update, *Central South Carolina Society Meeting*, Columbia, SC, July 23, 1996.
- (72) Presentation, New Medical Therapies in Glaucoma, *University of South Carolina Grand Rounds*, Columbia, SC, July 12, 1996.
- (73) Presentation, New Medical Therapies in Glaucoma, New Orleans, LA, July 26, 1996.
- (74) Presentation, Current Medicines in Glaucoma, *Xalatan launch meeting*, Dallas, Texas, August 21, 1996.
- (75) Presentation, Xalatan Overview, *Xalatan launch meeting*, Dallas, Texas, August 21, 1996.
- (76) Presentation, New Medicines in Glaucoma, *29th Panhellenic Ophthalmological Congress*, Greece, September 1996.
- (77) Presentation, Clinical Evaluation and Management of Low-Tension Glaucoma, *American Academy of Ophthalmology*, Chicago, October 1996.
- (78) Presentation, Current and Future Use of Glaucoma Medications, *American Academy of Ophthalmology*, Chicago, October 1996.
- (79) Presentation, Results of Cost Analysis of Glaucoma Chronic Dosing Therapy, *Betimol Advisory Board*, Chicago, October 28, 1996.
- (80) Presentation, Diurnal Curve of Intraocular Pressure with Rescula Treatment, Chicago, October 29, 1996.
- (81) Presentation, Current and Future Glaucoma Medications, *East Virginia Medical School*, Norfolk, VA, November 13, 1996.
- (82) Presentation, Grand rounds, *East Virginia Medical School*, Norfolk, VA, November 13, 1996.
- (83) Presentation, Current and Future Glaucoma Medications, Daytona Beach, FL, January 15, 1997.
- (84) Presentation, Xalatan and Alphagan Overview, Puerto Rico, February 12, 1997.
- (85) Participant, Panel Discussion, Puerto Rico, February 12, 1997.
- (86) Presentation, Treatment of Glaucoma, *Training Seminar*, Kalamazoo, Michigan, February 20, 1997.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (87) Presentation, Xalatan Overview, *Training Seminar*, Kalamazoo, Michigan, February 20, 1997.
- (88) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, April 7, 1997.
- (89) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, April 8, 1997.
- (90) Presentation, Current and future glaucoma medications, *Scandinavian Ophthalmology Meeting*, Iceland, April 18 - 20, 1997.
- (91) Participant, Panel Discussion, *Scandinavian Ophthalmology Meeting*, Iceland, April 18 - 20, 1997.
- (92) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Cancun, Mexico, May 3, 1997.
- (93) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, *Pan American Ophthalmology Conference*, Cancun, Mexico, May 3, 1997.
- (94) Presentation Rescula: A New Agent for the Treatment of Glaucoma, *International Congress of Glaucoma*, Sao Paulo, Brazil, May 8, 1997.
- (95) Participant, Panel Discussion, Betimol and Modern β -blocker Therapy, *Ophthalmology Times*, Fort Lauderdale, Florida, May 1997.
- (96) Presentation, Patient Management Considerations in Glaucoma, *EuroTransMed*, London, May 20, 1997.
- (97) Presentation, Xalatan Overview, *National Ophthalmics Speakers Program*, Quebec, Canada, June 13, 1997.
- (98) Presentation, Xalatan Overview, *Charleston Ophthalmology Society*, Charleston, South Carolina, July 8, 1997.
- (99) Presentation, Today's β -blocker therapies: The place of Betimol™ in the Commercial Market, Atlanta, Georgia, July 28, 1997.
- (100) Presentation, New and Future Drug use for Glaucoma, *American Academy of Ophthalmology*, San Francisco, California, October 27, 1997.
- (101) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, San Francisco, California, October 29, 1997.
- (102) Presentation, Current and Future Glaucoma Medications, Ottawa, Canada, November 5, 1997.
- (103) Presentation, Postoperative Complications of Filtering Surgery, *Training session*, Ottawa, Canada, November 5, 1997.
- (104) Presentation, Xalatan Overview, Charlotte, North Carolina, November 17, 1997.
- (105) Presentation, Current and Future Glaucoma Medications, *48th Annual Post-Graduate Review Course: Ophthalmology*, Syracuse, New York, December 5, 1997.
- (106) Presentation, Xalatan Overview, *48th Annual Post-Graduate Review Course: Ophthalmology*, Syracuse, New York, December 5, 1997.
- (107) Presentation, Treating Primary Open-Angle Glaucoma, *75th Southern Congress of Optometry*, Atlanta, Georgia, February 26, 1998.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (108) Presentation, Current and Future Glaucoma Medications, *San Antonio Ophthalmology Society*, San Antonio, Texas, February 28, 1998.
- (109) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Jerusalem, Israel, March 18, 1998.
- (110) Chairman, IOP Lowering Therapies, *2nd International Glaucoma Symposium*, Jerusalem, Israel, March 18, 1998.
- (111) Presentation, Treating Primary Open-Angle Glaucoma, Helsinki, Finland, March 27, 1998.
- (112) Presentation, Treating Primary Open-Angle Glaucoma, Tampere, Finland, March 27, 1998.
- (113) Presentation, Treating Primary Open-Angle Glaucoma, Stockholm, Sweden, March 28, 1998.
- (114) Moderator, Round-table discussion, Current β -blocker Therapy, *ARVO*, Fort Lauderdale Florida, May 10, 1998.
- (115) Presentation, Treating Primary Open-Angle Glaucoma, Halkadiki, Greece, May 27, 1998
- (116) Participant, Panel Discussion Combined Surgery, Halkadiki, Greece, May 28, 1998
- (117) Presentation, Development and Pharmacology of Latanoprost, Banff, Canada, June 25, 1998
- (118) Presentation, The Role of IOP in the Management of Glaucoma, Banff, Canada, June 25, 1998
- (119) Presentation, Update on Compliance, New York City, New York, July 17, 1998
- (120) Presentation, Development and Pharmacology of Latanoprost & Clinical Efficacy and Safety of Latanoprost, New Orleans, Louisiana, September 17, 1998
- (121) Presentation, Development and Pharmacology of Latanoprost & Clinical Efficacy and Safety of Latanoprost, San Antonio, Texas, September 18, 1998
- (122) Presentation, Treating Primary Open-Angle Glaucoma, *Glaucoma Symposium*, Richmond, Virginia, September 25, 1998
- (123) Presentation, New and Future Drug use for Glaucoma, *Risquez Hospital Post Graduate Course*, Caracas, Venezuela, October 2-4, 1998
- (124) Participant, Panel Discussion Treating Glaucoma, *Risquez Hospital Post Graduate Course*, Caracas, Venezuela, October 2-4, 1998
- (125) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, *Risquez Hospital Post Graduate Course*, Caracas, Venezuela, October 2-4, 1998
- (126) Presentation, Update on Compliance, *Risquez Hospital Post Graduate Course*, Caracas, Venezuela, October 2-4, 1998
- (127) Presentation, Treating Primary Open-Angle Glaucoma, *Risquez Hospital Post Graduate Course*, Caracas, Venezuela, October 2-4, 1998
- (128) Presentation, Treating Primary Open-Angle Glaucoma, Macon, Georgia, October 15, 1998
- (129) Presentation, Aggressive Lowering of IOP, *American Academy of Ophthalmology*, New Orleans, Louisiana, November 7, 1998

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (130) Presentation, The Role of IOP in the Management of Glaucoma, *American Academy of Ophthalmology*, New Orleans, Louisiana, November 8, 1998
- (131) Presentation, New and Future Drug use for Glaucoma, *American Academy of Ophthalmology*, New Orleans, Louisiana, November 11, 1998
- (132) Presentation, Pharmacology of Glaucoma Medications, *Inter-American Course, Bascom Palmer Eye Institute*, Miami, FL, November 18, 1998
- (133) Presentation, New Medical Therapy in Glaucoma: Making Clinical Decisions with Drugs, *Inter-American Course, Bascom Palmer Eye Institute*, Miami, FL, November 18, 1998
- (134) Presentation, The Role of IOP in the Management of Glaucoma, Banff, Canada, November 21, 1998
- (135) Presentation, The Role of IOP in the Management of Glaucoma, Winnipeg, Canada, December 5, 1998
- (136) Presentation, The Role of IOP in the Management of Glaucoma, Niagara-on-the-Lake, Ontario, March 27, 1999
- (137) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, *San Antonio Ophthalmological Society*, University of Texas, San Antonio, TX, April 17, 1999
- (138) Presentation, The Role of IOP in the Management of Glaucoma, Ottawa, Canada, April 24, 1999
- (139) Moderator, Rescula Advisory Board, Fort Lauderdale, FL, May 8, 1999
- (140) Presentation, Clinical Efficacy of Rescula, Fort Lauderdale, FL, May 8, 1999
- (141) Presentation, Position of Rescula in Glaucoma Therapy, Fort Lauderdale, FL, May 8, 1999
- (142) Presentation, Key Factors for Treatment Success in Glaucoma, *White Nights Ophthalmological Congress*, St. Petersburg, Russia, May 24 - 27, 1999
- (143) Presentation, Treating Primary Open-Angle Glaucoma, *Memphis Eye Society Annual Convention, University of Tennessee*, Memphis, TN, June 5, 1999
- (144) Presentation, New and Future Drug use for Glaucoma, *Memphis Eye Society Annual Convention, University of Tennessee*, Memphis, TN, June 5, 1999
- (145) Presentation, Update on Compliance, *Memphis Eye Society Annual Convention, University of Tennessee*, Memphis, TN, June 5, 1999
- (146) Presentation, Current Treatment of Glaucoma, *Pharmacist Society of NY*, Albany, NY, June 24, 1999
- (147) Presentation, Key Factors for Treatment Success in Glaucoma, *X11th Congress of the European Society of Ophthalmology*, Stockholm, Sweden, June 27 - July 1, 1999
- (148) Presentation, Treating Primary Open-Angle Glaucoma, *X11th Congress of the European Society of Ophthalmology*, Stockholm, Sweden, June 27 - July 1, 1999
- (149) Presentation, Rescula: A New Agent for the Treatment of Glaucoma, Buenos Aires, Argentina, August 20, 1999

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (150) Presentation, Current Treatment and Endpoints in Glaucoma, Buenos Aires, Argentina, August 20, 1999
- (151) Presentation, Current Treatment and Endpoints in Glaucoma, *McGill University*, Montreal, Canada, September 9, 1999
- (152) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Montreal, September 9, 1999
- (153) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Quebec City, September 10, 1999
- (154) Presentation, Development and Pharmacology of Latanoprost, Charleston, SC, September 25, 1999
- (155) Presentation, Switching Medicines in Glaucoma, *AAO*, Orlando, FL, October 23, 1999
- (156) Presentation, Role of IOP in Management of Glaucoma, *AAO*, Orlando, FL, October 24, 1999
- (157) Presentation, New and Future Medical Treatment for Glaucoma, *AAO*, Orlando, FL, October 26, 1999
- (158) Presentation, Treating Primary Open-Angle Glaucoma, *JCAHPO*, Orlando, FL, October 27, 1999
- (159) Presentation, Lessons from the Neurosciences, *ISOPP Congress*, Lisbon, Portugal, February 10, 2000
- (160) Chairman, Glaucoma Session, *ISOPP Congress*, Lisbon, Portugal, February 10, 2000
- (161) Participant, Panel Discussion, Blood Flow, *ISOPP Congress*, Lisbon, Portugal, February 10, 2000
- (162) Presentation, Stepwise Treatment of Glaucoma, *ISOPP Congress*, Lisbon, Portugal, February 10, 2000
- (163) Presentation, Clinical Results of Rescula, Islamorada, FL, March, 2000
- (164) Presentation, Efficacy and Safety of Cosopt, *National Glaucoma Congress*, Athens, Greece, March 31, 2000
- (165) Presentation, Mechanism of Xalatan, *Glaucoma Update 2000*, Miami, FL, April 7, 2000
- (166) Presentation, Efficacy & Safety of Cosopt, *Spring Ophthalmic Consultants' Conference*, Charleston, SC, April 15, 2000
- (167) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Budapest, Hungary, April 25, 2000
- (168) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Tallinn, Estonia, April 26, 2000
- (169) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, *2nd Polish Glaucoma Symposium*, Wroclaw, Poland, April 28, 2000
- (170) Presentation, Current Monotherapy in Glaucoma, London, Ontario, May 12, 2000
- (171) Presentation, Current Monotherapy in Glaucoma, Toronto, Ontario, May 13, 2000
- (172) Chairman, *Rescula United States Advisory Board*, St. Thomas, Virgin Islands, June 2-4, 2000
- (173) Presentation, Rescula Efficacy Update, St. Thomas, Virgin Islands, June 2-4, 2000

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (174) Presentation, Rescula Safety Update, St. Thomas, Virgin Islands, June 3, 2000
- (175) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Niagara on the Lake, Ontario, June 10, 2000
- (176) Presentation, Over view of Xalatan, Niagara on the Lake, Ontario, June 10, 2000
- (177) Presentation, Mechanism of Action of Xalatan, Las Vegas, Nevada, June 21, 2000
- (178) Presentation, Development and Pharmacology of Xalatan, New York, New York, August 12, 2000
- (179) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Tampere, Finland, September 1, 2000
- (180) Presentation, Clinical Trials of Unoprostone, New York, New York, September 16, 2000
- (181) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, *St. Louis Ophthalmological Society, Grand Rounds, St. Louis University*, St. Louis, Missouri, September 21, 2000
- (182) Presentation, New and Future Medical Treatment for Glaucoma, *Grand Rounds, St. Louis University*, St. Louis, Missouri, September 22, 2000
- (183) Presentation, Pharmacology and Clinical Effects of Xalatan, *International Society of Ocular Toxicology*, Kiawah Island, South Carolina, October 4, 2000
- (184) Presentation, Development and Pharmacology of Xalatan, Washington DC, October 14, 2000
- (185) Presentation, New and Future Medical Treatment for Glaucoma, *AAO*, Dallas, Texas, October 24, 2000
- (186) Presentation, Emerging Therapies in the Medical Management of Glaucoma, *AAO*, Dallas, Texas, October 22, 2000
- (187) Presentation, Development and Pharmacology of Xalatan, Dorado, Puerto Rico, November 4, 2000
- (188) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Ottawa, Ontario, November 14, 2000
- (189) Presentation, Clinical Results of Rescula, Biloxi, Mississippi, November 18, 2000
- (190) Presentation, Overview of Glaucoma, *Specialized Glaucoma Representative Training*, Peapack, New Jersey, February 13, 2001
- (191) Presentation, Overview of Ophthalmic Equipment, *Specialized Glaucoma Representative Training*, Peapack, New Jersey, February 13, 2001
- (192) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, *Grand Rounds, University of Cincinnati*, Cincinnati, Ohio, February 14, 2001
- (193) Presentation, Emerging Medical Treatment for Glaucoma, *Cincinnati Society of Ophthalmology*, Cincinnati, Ohio, February 14, 2001
- (194) Presentation, Adjunctive Therapy, Atlanta, Georgia, February 21, 2001

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (195) Presentation, Place of Rescula in Therapy, Atlanta, Georgia, February 21, 2001
- (196) Presentation, The Efficacy and Safety of Unoprostone in the Management of Glaucoma, *SECO International 2001*, Atlanta, Georgia, February 23, 2001
- (197) Presentation, IOP Control, Neuroprotection and Blood Flow: Putting It All Into Perspective, Halifax, Nova Scotia, March 3, 2001
- (198) Presentation, Efficacy and Safety of Cosopt, *8th International Congress on Glaucoma*, Athens, Greece, March 10, 2001
- (199) Presentation, Overview of Xalatan, AXIS, Anaheim, California, March 14, 2001
- (200) Presentation, New and Future Medical Treatment for Glaucoma, New York, New York, April 19, 2001
- (201) Chairman, Round-Table Discussion, *Rescula Advisory Board*, Fort Lauderdale, Florida, April 29, 2001
- (202) Presentation, Development and Pharmacology of Latanoprost, Montreal, Canada, May 4-6, 2001
- (203) Presentation, Pressure Control or Neuroprotection: Where are we in Glaucoma Therapy? Niagara-on-the-Lake, Canada, June 9, 2001
- (204) Presentation, Development and Pharmacology of Latanoprost, Keystone, Colorado, June 22-24, 2001
- (205) Chairman, Cascade Meeting, Keystone, Colorado, June 22-24, 2001
- (206) Presentation, Development and Pharmacology of Latanoprost, Toronto, Canada, August 17-19, 2001
- (207) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Columbus, Ohio, September 20, 2001
- (208) Presentation, New Prostaglandin Related Medicines, *Midwestern Glaucoma Society*, Sponsored by Washington University, St. Louis, Missouri, October 6, 2001
- (209) Presentation, Xalacom: The Dynamic Duo, *European Xalacom Launch*, Cannes, France, October 16, 2001
- (210) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Indianapolis, Indiana, November 1, 2001
- (211) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Louisville, Kentucky, November 7, 2001
- (212) Presentation, Research Methodology: Reading Between the Lines, *Laval University*, Quebec City, Canada, November 8, 2001
- (213) Presentation, Neuroprotection and Blood Flow: Putting it in Perspective, Quebec City, Canada, November 8, 2001
- (214) Presentation, Xalacom versus Combination Timolol and Alphagan, *American Academy of Ophthalmology*, New Orleans, Louisiana, November 12, 2001
- (215) Presentation, Medical Options for Primary Open-angle Glaucoma, Nashville, Tennessee, November 28, 2001

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (216) Speaker and Key Faculty, Xalatan Safety Update, *East Coast Summit Meeting*, Miami, Florida, December 1, 2001
- (217) Presentation, Importance of IOP, *European Xalacom Launch*, Cannes, France, January 16, 2002
- (218) Presentation, Study Design & Literature Analysis, *Glaucoma Science Liaison Training*, Banff, Alberta, Canada, January 19, 2002
- (219) Presentation, Clinical Review of Xalacom, *Xalacom Launch*, Caracas, Venezuela, February 21, 2002
- (220) Chairman, Round-Table Discussion, *Xalacom Launch*, Caracas, Venezuela, February 22, 2002
- (221) Presentation, Glaucoma Genetics, Clinical Applications: ISV-205, *International Symposium on Ocular Pharmacology and Pharmaceutics*, Seville, Spain, February 28, 2002
- (222) Moderator, Glaucoma Genetic Therapy Session, *International Symposium on Ocular Pharmacology and Pharmaceutics*, Seville, Spain, February 28, 2002
- (223) Presentation, Overview of Xalatan, *International Symposium on Ocular Pharmacology and Pharmaceutics*, Seville, Spain, February 28, 2002
- (224) Moderator, Latanoprost Update – The New “Gold Standard” for Medical Treatment of Intraocular Pressure, *International Symposium on Ocular Pharmacology and Pharmaceutics*, Seville, Spain, February 28, 2002
- (225) Presentation, Mechanism of Action between Prostaglandins, *Glaucoma Update (Cascade) Meeting*, Puerto Rico, April 6, 2002
- (226) Presentation, Importance of the Mean and Diurnal Curve Intraocular Pressures in Glaucoma, Evansville, Indiana, April 9, 2002
- (227) Presentation, Clinical Review of Xalacom, *Greek Glaucoma Symposium*, Athens, Greece, April 13, 2002
- (228) Presentation, Medical Options for Monotherapy, Southfield, Michigan, April 25, 2002
- (229) Presentation, Reading Between the Lines: An Interpretation of Clinical Studies, Magog, Quebec, Canada, April 27, 2002
- (230) Presentation, Xalacom versus Cosopt, *Xalacom Launch*, Paris, France, May 13, 2002
- (231) Presentation, Mechanism of Action between Prostaglandins, *Glaucoma Update (Cascade) Meeting*, Montreal, Quebec, Canada, May 18, 2002
- (232) Moderator, Managed Care Consultant Panel, *Glaucoma Update (Cascade) Meeting*, Montreal, Quebec, Canada, May 18, 2002
- (233) Presentation, Ocular Hyperemia and the Significance of the OHTS Trial, Chicago, Illinois, May 21, 2002
- (234) Presentation, Review of the New Prostaglandin Related Medicines in Comparison to Latanoprost, *35th Panhellenic Ophthalmological Congress, Sponsored by the Ophthalmology Society of Northern Greece and Pharmacia*, Chalkidiki, Greece, June 5, 2002
- (235) Presentation, New Prostaglandin Related Medicines, *Sponsored by the University of Missouri*, Kansas City, Missouri, June 15, 2002

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (236) Press Conference, Clinical Review of Xalacom, Bangkok, Hong Kong, June 27, 2002
- (237) Presentation, Clinical Review of Xalacom, Shantou, China, June 28, 2002
- (238) Presentation and Key Faculty, Neuroprotection and Blood Flow: Putting it into Perspective, *Glaucoma Update 2002 Cascade Meeting*, Boston, Massachusetts, July 13, 2002
- (239) Presentation, Importance of IOP and Diurnal Curve, Santiago, Chile, July 26, 2002
- (240) Presentation, Clinical Review of Xalacom, Santiago, Chile, July 26, 2002
- (241) Presentation, Glaucoma Medication Compliance Review, Santiago, Chile, July 26, 2002
- (242) Presentation, Clinical Review of Xalacom, *Ophthalmological Society of Malaysian Medical Association Meeting*, Kuala Lumpur, Malaysia, August 2, 2002
- (243) Presentation, Importance of IOP, *Ophthalmological Society of Malaysian Medical Association Meeting*, Kuala Lumpur, Malaysia, August 2, 2002
- (244) Presentation, Overview of Latanoprost, *5th Singapore National Eye Centre International Meeting and 5th Worldeyes International Meeting*, Singapore, August 3, 2002
- (245) Presentation, Importance of IOP, *5th Singapore National Eye Centre International Meeting and 5th Worldeyes International Meeting*, Singapore, August 3, 2002
- (246) Presentation, Clinical Review of Xalacom, Bangkok, Thailand, August 4, 2002
- (247) Presentation, Importance of IOP, Bangkok, Thailand, August 4, 2002
- (248) Presentation, Overview of Glaucoma, Toronto, Canada, August 23, 2002
- (249) Presentation, Medical Options for Monotherapy, Toronto, Canada, August 23, 2002
- (250) Presentation, Clinical Review of Xalacom, Porto, Portugal, September 14, 2002
- (251) Presentation, Clinical Review of Xalacom, Lisbon, Portugal, September 15, 2002
- (252) Presentation, Clinical Review of Xalacom, *National Sales Meeting*, Toronto, Canada, September 24, 2002
- (253) Presentation, Ocular Hypertension and the Importance of IOP, *SEAGIG Convention*, Manila, Philippines, September 27, 2002
- (254) Presentation, AXIS Update, AAO, Orlando, Florida, October 21, 2002
- (255) Presentation, Prostaglandin Therapy - What We Know Today, Marina del Ray, CA, November 2, 2002
- (256) Moderator, Glaucoma Managed Care Advisory Board Meeting, Marina del Ray, CA, November 2, 2002
- (257) Presentation, Clinical Review of Xalacom, Vancouver, Canada, February 8, 2003
- (258) Presentation, Importance of IOP, Vancouver, Canada, February 8, 2003
- (259) Presentation, Importance of IOP, *10th International Congress of Glaucoma*, Athens, Greece, February 22, 2003

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (260) Presentation, Clinical Review of Cosopt, *10th International Congress of Glaucoma*, Athens, Greece, February 22, 2003
- (261) Presentation, Controlling IOP with Cosopt, *Clinical Frontiers in Ophthalmology*, Krakow, Poland, March 8, 2003
- (262) Moderator, Speaker Forum, Cosopt IOP Lowering Efficacy, *Clinical Frontiers in Ophthalmology*, Krakow, Poland, March 9, 2003
- (263) Presentation, Achieving Powerful IOP Control in Clinical Practice, *4th International Glaucoma Symposium*, Barcelona, Spain, March 20, 2003
- (264) Co-Chair, Medical Therapy 2, *4th International Glaucoma Symposium*, Barcelona, Spain, March 22, 2003
- (265) Presentation, 24-hour Diurnal Curve Comparison of Bimatoprost versus Timolol Maleate/Dorzolamide Fixed Combination, *4th International Glaucoma Symposium*, Barcelona, Spain, March 22, 2003
- (266) Presentation, Controlling IOP with Cosopt, *National Glaucoma Congress*, Utrecht, Netherlands, May 23, 2003
- (267) Presentation, Ocular Blood Flow, *Glaucoma in the 21st Century*, Istanbul, Turkey, May 24, 2003
- (268) Presentation, Overview of Xalacom, *Glaucoma in the 21st Century*, Istanbul, Turkey, May 24, 2003
- (269) Presentation, Overview of Xalacom, *Eye² Eye Rounds*, Niagara-on-the-Lake, May 31, 2003
- (270) Presentation, Major Clinical Studies Comparing Latanoprost, Bimatoprost and Travoprost, Mont Tremblant, Quebec, June 10, 2003
- (271) Presentation, Current Clinical Status Between Latanoprost, Bimatoprost and Travoprost, Mont Tremblant, Quebec, June 10, 2003
- (272) Presentation, Overview of Xalacom, Mont Tremblant, Quebec, June 10, 2003
- (273) Presentation, Rationale of Glaucoma Prostaglandin F_{2α} Drugs, Boston, MA, June 29, 2003
- (274) Trainer, Workshop – Blood Flow Update, Vascular Risk Factors, *Blood Flow Update, Vascular Risk Factors – Slide Kit Review*, Cancun, Mexico, July 11, 2003
- (275) Presentation, Controlling IOP with Cosopt, *Blood Flow Update, Vascular Risk Factors – Slide Kit Review*, Cancun, Mexico, July 12, 2003
- (276) Presentation, Pharmaceutical Research Network, LLC, New York City, NY, July 16, 2003
- (277) Presentation, Achieving Powerful IOP Control in Clinical Practice, SEO, *79th Congreso de la Sociedad Espanola de Oftalmologia*, Valencia, Spain, October, 10, 2003.
- (278) Presentation, Future of Glaucoma Therapy, Savannah, Georgia, October 15, 2003.
- (279) Presentation, Importance of IOP, *EUCAN Product Planning Meeting*, London, England, October 22, 2003.
- (280) Presentation, Clinical Overview of Comparators, London, England, October 22, 2003.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (281) Presentation, Future of Glaucoma Therapy, *Central South Carolina Ophthalmological Society*, Columbia, South Carolina, October 28, 2003.
- (282) Presentation, Importance of IOP, Barcelona, Spain, November 22, 2003.
- (283) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Cologne, Germany, December 6, 2003.
- (284) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Bremen, Germany, January 17, 2004.
- (285) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Baden-Baden, Germany, January 24, 2004.
- (286) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Munich, Germany, February 14, 2004.
- (287) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Berlin, Germany, March 6, 2004.
- (288) Moderator, Prostaglandins in the Eye, *International Symposium on Ocular Pharmacology and Therapeutics*, Monte Carlo, Monaco, March 12, 2004.
- (289) Presentation, Persistency of Glaucoma Therapy, *International Symposium on Ocular Pharmacology and Therapeutics*, Monte Carlo, Monaco, March 12, 2004.
- (290) Presentation, Newer Developments in Glaucoma Treatment, *11th International Congress of Glaucoma*, Athens, Greece, March 13, 2004.
- (291) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Heidelberg, Germany, March 27, 2004.
- (292) Presentation, Overview of Rescula, *The Association for Research in Vision and Ophthalmology*, Fort Lauderdale, Florida, April 25, 2004.
- (293) Presentation, Prostaglandin Review, *American Society of Cataract and Refractive Surgery*, San Diego, California, May 2, 2004.
- (294) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Dusseldorf, Germany, May 15, 2004.
- (295) Presentation, Efficacy and Safety of Cosopt, Barcelona, Spain, May 21, 2004.
- (296) Presentation, Overview of Xalacom, Winnipeg, Manitoba, Canada, May 25, 2004.
- (297) Presentation, Blood Flow, *37th Panhellenic and International Congress*, Halkidiki, Greece, June 11, 2004.
- (298) Presentation, Overview of Fixed Combinations, *37th Panhellenic and International Congress*, Halkidiki, Greece, June 12, 2004.
- (299) Presentation, The Role of Prostaglandin Analogues in the Treatment of Glaucoma: Learnings from Recent Guidelines, Kuala Lumpur, Malaysia, June 21, 2004.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (300) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, *Hospital Universiti Sainz Malaysia*, Kota Bahru, Malaysia, June 22, 2004.
- (301) Presentation, The Role of Prostaglandin Analogues in the Treatment of Glaucoma: Learnings from Recent Guidelines, Penang, Malaysia, June 23, 2004.
- (302) Presentation, Emerging New Standard of Glaucoma Management, *Hong Kong Eye Hospital*, Kowoon, Hong Kong, June 24, 2004.
- (303) Presentation, Emerging New Standard of Glaucoma Management, Kowoon, Hong Kong, June 24, 2004.
- (304) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Taichung, Taiwan, June 25, 2004.
- (305) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Taipei, Taiwan, June 26, 2004.
- (306) Presentation, Fixed Combination Therapy in the Treatment of Glaucoma, Kaohsiung, Taiwan, June 27, 2004.
- (307) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Klink, Germany, July 3, 2004.
- (308) Presentation, Importance of IOP, Warsaw, Poland, September 12, 2004.
- (309) Presentation, Importance of IOP/Review of Latanoprost, *Progress in Glaucoma Therapy*, Wolfsburg, Germany, October 2, 2004.
- (310) Presentation, Importance of IOP/Review of Cosopt, *University of Liverpool*, Warrington Hospital, Cheshire, United Kingdom, November 15, 2004.
- (311) Presentation, Importance of IOP/Review of Cosopt, *Manchester Royal Eye Society*, Manchester, United Kingdom, November 15, 2004.
- (312) Presentation, Importance of IOP/Review of Cosopt, *University of Newcastle*, Newcastle, United Kingdom, November 16, 2004.
- (313) Presentation, Importance of IOP/Review of Cosopt, *James Cook University*, Chester, United Kingdom, November 16, 2004.
- (314) Presentation, Importance of IOP/Review of Cosopt, Swansea, Wales, United Kingdom, November 17, 2004.
- (315) Presentation, Importance of IOP/Review of Cosopt, *North Trent Ophthalmological Society*, Sheffield, United Kingdom, November 18, 2004.
- (316) Presentation, Importance of IOP/Review of Cosopt, *Norfolk/Norwich University*, Norwich, United Kingdom, November 19, 2004.
- (317) Presentation, 24-hr IOP Control with Travoprost, *12th Greek Glaucoma Congress*, Athens, Greece, March 5, 2005.
- (318) Presentation, Future of Glaucoma Therapy, *12th Greek Glaucoma Congress*, Athens, Greece, March 5, 2005.
- (319) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Sydney, Australia, March 14, 2005.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (320) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Brisbane, Australia, March 15, 2005.
- (321) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Perth, Australia, March 16, 2005.
- (322) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Adelaide, Australia, March 17, 2005.
- (323) Presentation, Long-Term Implications of Treating Glaucoma - Update on Latanoprost, Melbourne, Australia, March 18, 2005.
- (324) Presentation, Update on the Latanoprost/Timolol Fixed Combination, *20th Asia Pacific Academy of Ophthalmology Congress*, Kuala Lumpur, Malaysia, March 28, 2005.
- (325) Press brief, Update on the Latanoprost/Timolol Fixed Combination, *20th Asia Pacific Academy of Ophthalmology Congress*, Kuala Lumpur, Malaysia, March 28, 2005.
- (326) Presentation, Update on Latanoprost, *VIII International Congress of the Pan Arab African Council of Ophthalmology*, Dubai, United Arab Emirates, April 8, 2005.
- (327) Presentation, Overview of Medical Glaucoma Treatments, Riyadh, Saudi Arabia, June 5, 2005.
- (328) Presentation, Overview of Medical Glaucoma Treatments, Damman, Saudi Arabia, June 6, 2005.
- (329) Presentation, Overview of Medical Glaucoma Treatments, Jeddah, Saudi Arabia, June 7, 2005.
- (330) Presentation, Update on Latanoprost, *AfME Ophthalmology Symposium*, Cairo, Egypt, June 9, 2005.
- (331) Presentation, Overview of Diurnal Fluctuation, *Turkish Ophthalmic Society Meeting*, Ankara, Turkey, September 20, 2005.
- (332) Presentation, Prostaglandin analogues: clinical efficacy and adjunctive therapy management, *Turkish Ophthalmic Society Meeting*, Ankara, Turkey, September 20, 2005.
- (333) Presentation, Update on the Latanoprost/Timolol Fixed Combination, *Korean Ophthalmology Autumn Congress*, Seoul, Korea, October 8, 2005.
- (334) Presentation, Importance of IOP and Review of Cosopt, *Asian Angle-Closure Glaucoma Club Annual Congress*, Taipei, Taiwan, October 29, 2005.
- (335) Presentation, Importance of IOP, *Asian Angle-Closure Glaucoma Club Annual Congress*, Taipei, Taiwan, October 30, 2005.
- (336) Presentation, Travoprost adjunctive therapy study (TATS), *TATS Investigators Meeting and Speakers Training*, Athens, Greece, February 11, 2006.
- (337) Interview, Betimol, Vistakon Pharmaceuticals, *2006 National Sales Meeting*, Palm Springs, Florida, February 28, 2006.
- (338) Session moderator, Target pressures in glaucoma therapy, *Alcon National Masters Club*, Las Vegas, Nevada, March 13, 2006.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (339) Presentation, Overview of Fixed Combination Therapy, *Alcon National Masters Club*, Las Vegas, Nevada, March 13, 2006.
- (340) Presentation, Overview of diurnal fluctuations, *V Russian Ophthalmic School*, Moscow, Russia, March 17, 2006.
- (341) Presentation, Prostaglandin analogues: clinical efficacy and adjunctive therapy management, Dusseldorf, Germany, March 24, 2006.
- (342) Presentation, Ocular Blood Flow and Glaucoma, *CEE-Istanbul University Program*, Istanbul, Turkey, March 25, 2006.
- (343) Session moderator, Does ocular blood flow really matter despite of strong IOP reduction, *CEE-Istanbul University Program*, Istanbul, Turkey, March 25, 2006.
- (344) Presentation, 24-hour IOP Control and the Benefits of PM Dosing, *3rd AfME Ophthalmology Forum*, Dubai, United Arab Emirates, April 13, 2006.
- (345) Presentation, An Overview of Monotherapy and Fixed Combination Therapy, *3rd AfME Ophthalmology Forum*, Dubai, United Arab Emirates, April 13, 2006.
- (346) Session chair, Xalacom Speaker Training, *3rd AfME Ophthalmology Forum*, Dubai, United Arab Emirates, April 13, 2006.
- (347) Presentation, Overview of Fixed Combination Therapy, *5th Glaucoma Symposium*, Wroclaw, Poland, April 21, 2006.
- (348) Presentation, Overview of prostaglandin therapy, *13th Annual Scientific Meeting of the Canadian Society of Cataract and Refractive Surgery*, Montreal, Quebec, Canada, April 23, 2006.
- (349) Presentation, Clinical review of the latanoprost/timolol fixed combination, *39th Panhellenic Ophthalmological Congress*, Thessaloniki, Greece, June 9, 2006.
- (350) Presentation, PG analogs as a first line treatment of glaucoma in the US, Lodz, Poland, June 12, 2006.
- (351) Presentation, The role of prostaglandin based fixed combinations in the treatment of glaucoma, Lodz, Poland, June 12, 2006.
- (352) Presentation, Overview of Diurnal Fluctuation, Siena, Italy, June 16, 2006.
- (353) Presentation, Overview of Fixed Combination Therapy, Sydney, Australia, July 23, 2006.
- (354) Presentation, CM 05-10 ADAPT: Brinzolamide compared to placebo when added to travoprost/timolol fixed combination, Investigator meeting, Sydney, Australia, July 23, 2006.
- (355) Presentation, Overview of Fixed Combination Therapy, Cape Town, South Africa, August 22, 2006.
- (356) Presentation, Overview of Fixed Combination Therapy, Port Elizabeth, South Africa, August 22, 2006.
- (357) Presentation, Overview of Fixed Combination Therapy, Johannesburg, South Africa, August 22, 2006.
- (358) Presentation, Overview of Fixed Combination Therapy, Durban, South Africa, August 22, 2006.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (359) Presentation, Overview of Fixed Combination Therapy, Investigator meeting, Montreal, Canada, November 18, 2006.
- (360) Presentation, CM 05-10 ADAPT: Brinzolamide compared to placebo when added to travoprost/timolol fixed combination, Investigator meeting, Montreal, Canada, November 18, 2006.
- (361) Presentation, Overview of Fixed Combination Therapy, Investigator meeting, Frankfurt, Germany, December 16, 2006.
- (362) Presentation, CM 06-12: Success of switching to the travoprost/timolol fixed combination from prior mono- or adjunctive therapy in Germany, Investigator meeting, Frankfurt, Germany, December 16, 2006.
- (363) Presentation, Overview of Prostaglandin Therapy, Glaucoma Update Meeting, Oxfordshire, England, March 10, 2007.
- (364) Presentation, Travoprost-based IOP control in primary and adjunctive treatment, Izmir, Turkey, March 19, 2007.
- (365) Presentation, Travoprost-based IOP control in primary and adjunctive treatment, Adana, Turkey, March 19, 2007.
- (366) Presentation, Pseudoexfolitive Glaucoma, Lindberg Society, *International Glaucoma Symposium*, Athens, Greece, March 31, 2007.
- (367) Presentation, Overview of glaucoma and research methods, Zurich, Switzerland, August 24, 2007.
- (368) Presentation, Overview of Prostaglandin Therapy, Orford, Quebec, Canada, September 15, 2007.
- (369) Moderator, Poster session 3: Neuro-ophthalmology / Strabismology / Paediatric / History, Glaucoma, Physiology/Biochemistry/Pharmacology, *European Association for Vision and Eye Research*, Portoroz, Slovenia, October 6, 2007.
- (370) Moderator, AMD advisory board, *American Academy of Ophthalmology*, November 10, 2007.
- (371) Moderator, Glaucoma advisory board, *American Academy of Ophthalmology*, November 11, 2007.
- (372) Presentation, Inspire Protocol 041-103, Investigator meeting, Raleigh, NC, December 8, 2007.
- (373) Presentation, Loteprenol Etabonate: A New Generation Steriod Against Ocular Inflammation, *41st Panhellenic Ophthalmological Congress*, Thessaloniki, Greece, May 29, 2008.
- (374) Presentation, Prostaglandin Update: 2008, *41st Panhellenic Ophthalmological Congress*, Thessaloniki, Greece, May 30, 2008.
- (375) Presentation, Second line therapy with Cosopt or Xalacom versus adding Cosopt to Xalatan monotherapy, *41st Panhellenic Ophthalmological Congress*, Thessaloniki, Greece, May 30, 2008.
- (376) Moderator, Rescula Advisory Board, *American Academy of Ophthalmology*, San Francisco, CA, October 25, 2009.
- (377) Presentation, Rescula safety, tolerability and efficacy, *American Academy of Ophthalmology*, San Francisco, CA, October 25, 2009.

WILLIAM C. STEWART, MD

INVITED LECTURES (continued)

- (378) Presentation, Where do we get all those new medicines anyway? The challenge of today's new drug development, West Haven, CT, July 17, 2011.
- (379) Presentation, The Placebo Effect in Glaucoma Trials: Impact, Potential Causes And Solutions, Acucela Investigator Meeting, Chicago, IL, August 13, 2011.
- (380) Presentation, The Placebo Effect in Glaucoma Trials: Impact, Potential Causes And Solutions, Altheos Investigator Meeting, San Francisco, CA, December 3, 2011.
- (381) Presentation, ARVO Workshop: Starting a company, Ophthalmic start-up CEO's perceptions of development hurdles, *The Association for Vision and Research in Ophthalmology*, Seattle, Washington, May 2, 2016.

MISCELLANEOUS

- (1) Stewart WC: Glaucoma: When to treat and what to use. **Audio Digest Ophthalmology**, Volume 32, Number 04, February 17, 1994, ISSN 0271-1281.

FELLOWS

Research Fellows:

Mark A. Cascairo, D.O.
Tod A. McMillan, M.D.
David R. Gwynn, M.D.
Gesa A. Stroman, M.D.
Sirus Hamzavi, M.D.
Xiao-hong Wang, M.D.
Tarek Ragaiey, Ph.D.
Chris Lopresto, M.D.
Wen-Jing Jiang, M.D.
Savvas Diafas, M.D.
Qasim Nasser, M.D.

Clinical Fellows:

Hugh L. Hennis, M.D.
Matthew J. Nutaitis, M.D.

ACADEMIA

- (1) Editorial board, **Journal of Glaucoma**, 1991 - 1994.
- (2) Review board member for **Journal of Glaucoma**, 1991 –
- (3) Review board member for **American Journal of Ophthalmology**, 1991 –
- (4) Review board member for **Archives of Ophthalmology**, 1992 –
- (5) Review board member for **Archives of Dermatology**, 1991 – 1996
- (6) Review board member for **Investigative Ophthalmology and Visual Science**, 1994
- (7) Review board member for **Survey of Ophthalmology**, 1994 –
- (8) Review board member for **SLACK, Inc.**, 1990.
- (9) Review board member for **Ophthalmology**, 1995 –
- (10) Review board member for **Ophthalmic Surgery**, 1996 –
- (11) Review board member for **British Journal of Ophthalmology**, 1999 –
- (12) Review board member for **Medical Letter**, 1997 –
- (13) Review board member for **Comprehensive Ophthalmology**, 2000 –
- (14) Review board member for **Eye**, 2000 –
- (15) Review board member for **Ocular Surgery & Lasers**, 2002 –
- (16) Review board member for **Acta Ophthalmologica Scandinavica**, 2002.
- (17) Review board member for **Drugs & Aging**. 2004 –
- (18) Review board member for **European Journal of Ophthalmology**. 2004 –
- (19) Instructor for **Merck, Sharp and Dohme Corporation**, 1989 -
- (20) Program Committee, **American Glaucoma Society**, 1990-1993.
- (21) Glaucoma Advisory Committee, **Prevent Blindness America**, 1990 - 1996.
- (22) Ethics committee, **South Carolina Society of Ophthalmology**, 1991.
- (23) Organizing board and Chairman of the Glaucoma section of **International Symposium on Experimental & Ocular Pharmacology and Pharmaceutics**, 1995 –2004.
- (24) Editorial board, **Ophthalmologia** (Greece), 2004.
- (25) Editorial board, **Acta Ophthalmologica Scandinavica**, 2007 –
- (26) Editorial board, **Journal of Ocular Pharmacology and Therapeutics**, 2008.

MEETINGS DEVELOPED

- (1) Diagnostic and therapeutic update in glaucoma, Kiawah, SC, April, 1991.
- (2) Investigator meeting, Tampere, Finland, August, 2002.
- (3) Investigator meeting, Toronto, Ontario, Canada, August 2002.
- (4) Investigator meeting, Barcelona, Spain, November 2003.
- (5) Investigator meeting, Warsaw, Poland, August, 2004.
- (6) Investigator meeting, Wroclaw, Poland, April, 2006.
- (7) Investigator meeting, Sydney, Australia, July 2006.
- (8) Investigator meeting, Montreal, Canada, November 2006.
- (9) Investigator meeting, Frankfurt, Germany, December 2006.